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General Introduction

11General introduction
1 Peritoneal dialysis in children
Experience with peritoneal dialysis in children has been described for the ﬁ rst time in 1948; 
it soon became an accepted treatment modality in acute renal failure (1,2,3). However 
it was not until the introduction of continuous ambulatory peritoneal dialysis (CAPD) 
in adults by Popovich and Moncrief in 1976 (4), that pediatric nephrologists became 
interested to apply peritoneal dialysis in end stage renal disease. In CAPD a permanent 
catheter is surgically or percutaneously implanted into the peritoneal cavity of the patient 
and is used for the instillation and drainage of the dialysis solution by gravity. Th is is per-
formed 3 to 5 times per day. CAPD allows children of all ages to receive dialysis at home 
guaranting a more normal childhood. Th e technique oﬀ ers advantages over hemodialysis 
like the reduced dietary restrictions and the absence of repeated needle punctures. Price 
and Suki ﬁ rst introduced the use of an automated cycler in pediatric peritoneal dialysis 
in 1981 (5). In continuous cycling peritoneal dialysis (CCPD) exchanges are performed 
by a machine instead of manual exchanges based on gravity. Th e introduction of CCPD 
was the onset of the development of one of the most popular dialysis regimens used in 
children: nightly intermittent peritoneal dialysis (NIPD), characterized by approximately 
5 to 9 short term dwells during the night, which allows for discontinuation of dialysis 
during the day. Because dwell times during NIPD are much shorter compared to CAPD, 
and maximum ﬂ uid removal takes place at the beginning of the dwell, NIPD allows more 
freedom in ﬂ uid intake. Th e empty abdomen during the day also releases the child and 
his or her parents from worries concerning dialysis.
Th e development of portable cyclers during the last 5 to 10 years has further improved 
the quality of life, since treatment is not any longer restricted to a ﬁ xed place. In Th e 
Netherlands many families have gained excellent experiences with camping holidays since 
the introduction of the portable cycler. Adaptations to the current cyclers, allowing very 
small volumes and decreased ﬂ ow velocities, will also allow very small infants to use a 
portable cycler.
End stage renal disease is not a common pediatric disorder and as a consequence children 
account for only a small fraction of the total dialysis patient counts. For example only 
2.6% of registered PD patients in the United States were less than 20 years of age in 
1996, while 60% of pediatric dialysis patients younger than 15 years were treated with 
peritoneal dialysis (1). In the Netherlands 58.4% (range 50.9-68.1) of pediatric patients 
on chronic renal replacement therapy have been treated with peritoneal dialysis during 
the last decade (1993-2002). Especially in the age group under 13 years peritoneal dialysis 
is the most popular dialysis modality (data obtained from Renal Replacement Registry 
Netherlands). (Table 1).
Peritoneal dialysis is the dialysis treatment modality most commonly prescribed for chil-
dren with end stage renal disease throughout large parts of the world (6). In pediatric 
peritoneal dialysis only limited studies with respect to the preservation of the stability of 
the peritoneum are available. Th is is mainly caused by the relatively short average dialy-
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sis periods in this patient category (7). On the other hand, the relatively low morbidity 
and mortality rates did not act as driving forces for this kind of studies. It should be 
remembered however, that although most children on dialysis are the recipients of a renal 
transplant, sooner or later the subsequent transplant failure will necessitate resumption 
of dialysis and therefore require the prolonged functionality of the peritoneal membrane 
as a dialyzing membrane.
Studies on transport kinetics in adult patients have been standardized since the introduction 
of the peritoneal equilibration test (PET) as prescribed by Twardowski (8). Standard dwell 
volumes of 2 L are generally used, regardless of the patient’s size. Nevertheless comparison 
of studies on transport kinetics in children with the adult data was hard to make since 
diﬀ erent intraperitoneal volumes were used. Some studies used intraperitoneal volumes 
scaled to body weight (9,10), body surface area (11) or both (12,13). Based on recent stud-
ies consensus has been reached that PET should be performed with a volume calculated 
according to body surface area, since the body surface area is roughly proportional to the 
surface area of the peritoneal membrane (14). De Boer et al. demonstrated an age-inde-
pendency across the pediatric age range for peritoneal membrane transport parameters if 
transport parameters were evaluated with a test volume related to body surface area (15). 
Several studies have conﬁ rmed this (11,16,17). Bouts et al. also demonstrated that no dif-
ferences are found in peritoneal ﬂ uid and solute transport characteristics between children 
and adults when results are corrected for body surface area (17). 
As mentioned previously there is only limited knowledge of the long-term functionality 
of the pediatric peritoneal membrane. Th e results of some long-term follow-up studies 
performed in children all suggest that there is no eﬀ ect of time on peritoneal dialysis on 
the transport parameters, suggesting a transport stability of the pediatric peritoneal perme-
0 – 2 years 3 - 12 years 13 – 17 years 0 – 17 years
PD HD PD HD PD HD PD HD
1993 71.4 28.6 64.3 35.7 37.5 62.5 54.3 45.7
1994 100 0 70.5 29.5 44.1 55.9 61.4 38.6
1995 100 0 73.3 26.7 58.3 41.7 68.1 31.9
1996 87.5 12.5 55.6 44.4 46.7 53.3 55.4 44.6
1997 75.0 25.0 73.5 26.5 43.5 56.5 62.3 37.7
1998 71.4 28.6 70.6 29.4 42.1 57.9 61.7 38.3
1999 77.8 22.2 61.0 39.0 32.0 68.0 53.3 46.7
2000 55.6 44.4 62.2 37.8 54.3 45.7 58.0 42.0
2001 60.0 40.0 60.0 40.0 57.1 42.9 58.7 41.3
2002 83.3 16.7 56.6 43.5 39.3 60.7 50.9 49.1
Table 1. Ratio peritoneal dialyis (PD) – hemodialysis (HD) in children in Th e Netherlands. 
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ability (6,16,17, 18). It should be remembered again, that treatment periods in pediatric 
peritoneal dialysis are relatively short. Reports on the inﬂ uence of peritonitis are contradic-
tory. Hölttä et al (16) saw no change of peritoneal membrane function after episodes of 
peritonitis, while Warady et al (6) reported a trend toward an increase in transport capacity 
for solutes, like glucose and creatinine. Also Andreoli et al. concluded that children with a 
history of peritonitis have a peritoneal membrane that is more permeable to glucose and 
creatinine. Consequently the osmotic gradient will dissipate faster, which could eventu-
ally contribute to ultraﬁ ltration failure (19). With respect to the inﬂ uence of peritonitis 
episodes in adults there also are conﬂ icting reports in this ﬁ eld. Where one group observed 
recurrent peritonitis giving rise to an increase in solute transport (20), the other did not 
see a signiﬁ cant inﬂ uence on solute transport or ﬂ uid kinetics (21).
2 The peritoneal membrane
During the evolution of species, the peritoneal cavity lost its original function as an excre-
tory organ, but with the insertion of an appropriate catheter into the peritoneal cavity we 
are able to restore this excretory function (22). In peritoneal dialysis a biological membrane 
lining the peritoneal cavity, the peritoneal membrane, is used to remove uremic toxins and 
water from the patient. Th e peritoneal membrane is composed of three diﬀ erent compart-
ments: vasculature, interstitium and mesothelium, each composed of diﬀ erent types of 
cells: endothelial cells in the capillary walls, ﬁ broblasts in the interstitium and mesothelial 
cells in the mesothelium. 
2.1 The mesothelium
It is generally believed that the mesothelium is not an important barrier to solute transport 
since there was no osmotic pressure gradient found across it during peritoneal dialysis in rats 
(23,24) as was investigated by measuring the hydrostatic pressure proﬁ les in the abdominal 
wall during conditions of isotonicity and hypertonicity. However the mesothelial layer was 
shown to have a sophisticated junctional complex, a carpet of microvillous projections 
at the free surface and a cytoplasm replete with organelles (22) and must be considered 
having the properties of an epithelium with a selective barrier of permeability (25). Also 
the existence of facilitative glucose transporters in mesothelial cells has been demonstrated 
(26). Th is suggests that the mesothelial cells could participate in the osmotic barrier dur-
ing peritoneal dialysis by conditioning glucose transcellular transport, or by diﬀ usion 
mediated by glucose transport or even by regulation of solute and water ﬂ uxes through 
tight junction modulation (25). However in vivo transport experiments performed in rats 
showed that the removal of the mesothelium does not result in a marked enhancement 
of transport of ﬂ uid and small solutes and thus supports the idea that the mesothelium is 
not a rate-limiting barrier (27). 
2.2 The interstitium
Th e interstitial space between the peritoneal vasculature and cells like parenchymal cells 
and ﬁ broblasts is ﬁ lled with extracellular matrix. Th is extracellular matrix gives the tissue 
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its mechanical and physicochemical properties and acts as a framework for cell attachment 
and migration (28). Hyaluronan, a soluble glycosaminoglycan, is a major component of 
the extracellular matrix (29). Th is polysaccharide is found in all tissues and body ﬂ uids and 
participates in ﬂ uid homeostasis, response to inﬂ ammation and wound healing (29,30). 
Increasing evidence suggests that the hyaluronan content in the interstitium is one of the 
major determinants of the resistance to transperitoneal transport of water and solutes (23, 
31‒34). Hyaluronan seems to increase the diﬀ usion coeﬃ  cient for solutes (35) and seems 
to exert eﬀ ect on the hydraulic conductivity of tissues involved (33,34). However it is still 
poorly understood how hyaluronan acts within the tissue to modulate transport (34, 36). In 
chronic peritoneal dialysis it is possible that the peritoneal membrane content of hyaluronan 
is reduced, since hyaluronan may be washed out, thereby increasing the interstitial hydraulic 
conductivity (37). Recent studies suggest that intraperitoneally administered hyaluronan 
(added to the dialysis ﬂ uid), improves the eﬃ  ciency of ultraﬁ ltration during peritoneal 
dialysis by reducing the peritoneal ﬂ uid back-ﬁ ltration. Th is eﬀ ect is dependent both on 
molecular weight and concentration of hyaluronan (38,39) and is thought to be the result 
of the impact of hyaluronan exerted on the peritoneal surface area. When added repeat-
edly to the peritoneal dialysis ﬂ uid during a longer period, hyaluronan seems to aﬀ ect the 
hydraulic conductivity of the interstitium: the increase in peritoneal solute transport rate, 
caused by repeated exposure to hypertonic glucose solutions was prevented in a group of 
Sprague-Dawley rats after repeated intraperitoneal use of hyaluronan (40).
2.3 The capillary wall
Th e peritoneal capillary wall is generally assumed to be the main barrier to transperitoneal 
transport of solutes in peritoneal dialysis. Th e capillaries of both the parietal and the vis-
ceral peritoneum are mainly of the continuous type, but 1.7% of the capillaries have been 
reported to be fenestrated (41). Th e fenestrae in these capillaries have been suggested to be 
the ultrastructural equivalent of the large pores, which represent a non-size-selective pathway 
for macromolecules. However the size of the fenestral openings is too large (60-90 nm) to 
be considered the structural equivalent of the hypothetical large pores (radii of 11-35 nm) 
and the density of these pores is substantially lower than the density of fenestrae (42). 
Tight junctions link the capillary endothelial cells to each other. Th ese tight junctions 
consist of protein molecules such as occludin and cadherin (43,44). Especially occludin 
creates a barrier to diﬀ usion of solutes (43). Th e tight junctions are probably the equivalent 
of the small pore system. 
During the last decade the presence of aquaporin-1, a transmembrane water channel protein, 
was demonstrated in the endothelial cell surface of peritoneal capillaries (45‒,47). Recently 
the expression of aquaporin-1 was also demonstrated in human peritoneal mesothelial cells 
(48) and in rat peritoneal venular endothelial cells (49). Although ten diﬀ erent aquaporins 
have been identiﬁ ed in man, several studies make it likely that aquaporin-1 is the chief 
candidate to represent the ultrasmall-pore system (49‒51).
15General introduction
3 Peritoneal solute and ﬂ uid transport
Th e biological character of the membrane used in peritoneal dialysis, requires a good un-
derstanding of the transport pathways in order to achieve an appropriate dose of dialysis 
for every individual patient. Despite of extensive studies on the kinetics of solute and 
ﬂ uid removal from the peritoneal cavity during peritoneal dialysis, our understanding of 
transperitoneal transport is still not complete. 
Figure 1 summarizes the current understanding of the routes for peritoneal solute and 
ﬂ uid transport. Th e changes in intraperitoneal volume during peritoneal dialysis are the 
result of ﬂ uid transport from the blood to the peritoneal cavity, and the removal of ﬂ uid 
out of the peritoneal cavity. 
3.1 Transport into the peritoneal cavity
For transport of ﬂ uid from the blood to the peritoneal cavity, osmotic and oncotic induced 
ultraﬁ ltration plays an important role (see paragraph 3.3). Removal of uremic toxins across 
the peritoneal membrane occurs by two major mechanisms: diﬀ usion and convection (35, 
52, 53). Diﬀ usion is the most important transport mechanism for low molecular weight 
solutes, and occurs bi-directional depending on the concentration gradient between blood 
and the dialysis ﬂ uid in the peritoneal cavity. Th e product of the mass transfer area coef-
ﬁ cient (MTAC; the maximum theoretical clearance by diﬀ usion at time zero, when no 
solute transport
fluid transport
peritoneal membrane peritoneal cavity
diffusion
convection
transcapillary
ultrafiltration
fluid absorption
lymphatics
peritoneal capillaries
interstitium
Figure 1. Routes for peritoneal transport of solutes and ﬂ uid. Solute transport occurs by 
either diﬀ usion or convection. Fluid transport occurs by either osmotic or oncotic induced 
transcapillary ultraﬁ ltration or by absorption out of the peritoneal cavity directly into the 
peritoneum or via the lymphatic vessels.
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transport has taken place yet) and the concentration gradient between blood and dialysis 
solution determines the rate of diﬀ usion (35). Diﬀ usion is a size-selective process, which 
means that small molecules diﬀ use at a faster rate than larger molecules, due to diﬀ erences 
in their free diﬀ usion coeﬃ  cient (53).
Convective transport of solutes occurs when equilibrium is present between plasma and 
the dialysis ﬂ uid. Transport of solutes is then determined by the net water transport be-
tween plasma and dialysate. Th e rate of convective transport is limited by two factors: 1) 
solute sieving and 2) ﬂ uid absorption from the peritoneal cavity. Th e sieving of solutes 
is determined by the ratio between the dialysate concentration of a solute and its plasma 
concentration when no transport by diﬀ usion occurs. It can range between 0 (no convective 
transport at all) and 1.0 (the membrane does not hinder convective transport) (35).
3.2 Transport out of the peritoneal cavity 
During peritoneal dialysis, ﬂ uid is lost from the peritoneal cavity into the tissues surround-
ing the peritoneal cavity and via the lymphatic vessels. Th e hydraulic pressure within the 
peritoneal cavity mainly determines the loss of ﬂ uid from the peritoneal cavity, which 
is in contrast with the crystalloid osmotic and colloid osmotic driven transport into the 
peritoneal cavity (54). A hydrostatic driven ﬂ ux of ﬂ uid and solutes occurs into the tissues 
surrounding the peritoneal cavity, subsequently followed by absorption into the intratissue 
lymphatics (54). Besides this hydrostatic pressure driven transport, ﬂ uid is also transported 
from the peritoneal cavity by subdiaphragmatic lymphatics. Th e lymphatic openings, also 
called stomata, permit absorption of intraperitoneal particles, cells, colloids and ﬂ uid (55). 
Th is lymphatic absorption takes place as a result of excursions of the diaphragm during 
respiration. Th e majority of investigators agree that ﬂ uid absorption directly into the tis-
sues surrounding the peritoneal cavity is the predominant way governing ﬂ uid loss from 
the peritoneal cavity (54). 
Based on our current knowledge of peritoneal transport mechanisms there remains dif-
ﬁ culty in understanding how ﬂ uid absorption into peritoneal tissues and transperitoneal 
ultraﬁ ltration can occur at the same time. Based on the knowledge that during a normal 
dwell only a fraction of the anatomical surface area of the peritoneal membrane comes in 
contact with the dialysis solution (56), Leypoldt suggested that a small amount of ﬂ uid 
will permeate regions of the peritoneum that are not in contact with dialysate, where the 
ﬂ uid will lose its osmotic solutes and will be absorbed due to the hydraulic pressure in the 
peritoneal cavity (52). 
Several studies concerning peritoneal ﬂ uid kinetics refer to the amount of ﬂ uid loss from 
the peritoneal cavity using the term ‘lymphatic absorption rate’. Since the disappearance 
of a marker is used to measure ﬂ uid loss from the peritoneal cavity (both into the sur-
rounding tissues and by subdiaphragmatic lymphatics) we prefer to use the term marker 
clearance instead of lymphatic absorption.
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3.3 The three-pore model
Although quite simple, the “three-pore model” developed by Rippe et al is still the most 
applied mathematical approach of the intraperitoneal volume versus time relationships 
under various conditions in peritoneal dialysis (57‒60). Th is computer model only takes 
into account the transport barrier of peritoneal capillary wall and neglects the mesothelium 
and the interstitium. Several other published models also take into account the interstitium 
and the mesothelium, but even though they are more accurate in describing transperitoneal 
transport (61,62) their complexity refrains them from being used (59). 
According to the three-pore model the peritoneum behaves as a membrane having three 
diﬀ erent types of functional pores: the water-exclusive aquaporins, the small-pore pathways 
and the large-pore pathways (Figure 2). Th e frequencies of the pores are inversely related 
to their pore sizes. Th us there are approximately 106 aquaporins and 104 small pores on 
every large pore (63). 
Th e small pores represent the major exchange pathway for small hydrophylic solutes and 
for water (58). Fluid transport is determined by crystalloid and colloid osmotic pressures. 
Th e crystalloid osmotic pressure gradient during peritoneal dialysis with conventional 
solutions is determined mainly by glucose (35). Its eﬀ ectiveness as an osmotic agent de-
pends on the resistance the membrane exerts to glucose transport. Th is is expressed as the 
osmotic reﬂ ection coeﬃ  cient, σ (35). It can range from 1 (no passage, ideal semipermeable 
membrane) to 0 (passage not hindered). A value of 0.03 for glucose has been calculated 
in CAPD patients (64). 
Th e large pores allow for a slow, unidirectional ﬂ ux of macromolecules and ﬂ uid from 
blood to the peritoneal cavity. Th is transport is driven by hydraulic forces (57‒59,64). 
Computer modeling according to a two-pore formalism of peritoneal transport (taking 
into account transport across the large and the small pores) allowed for calculation of the 
Figure 2. Th ree-pore model of peritoneal transport of solutes and water
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individual contribution of each pore system. Th e large pores are likely to contribute 5 to 
6% to transcapillary ultraﬁ ltration (59). Colloid osmotic forces are negligible across this 
pore system (65).
Th e existence of a third pathway was postulated to be a water-only pathway that rejects 
solute transport (57‒59). Computer simulations of peritoneal transport revealed that this 
water-only pathway allows for nearly one half of the ultraﬁ ltration using conventional 
glucose solutions (57). Th is was conﬁ rmed in an in vivo study (66). Th e reﬂ ection coef-
ﬁ cient of glucose will approach 1.0 across these ultrasmall pores, which might explain why 
glucose is such an eﬀ ective osmotic agent despite its small size (35). 
4 Methods to evaluate peritoneal transport characteristics
Th e most widely used approach to evaluate peritoneal transport characteristics in individual 
patients is the performance of a Peritoneal Equilibration Test (PET) in order to measure 
the dialysate to plasma solute concentration ratio (D/P) for small solutes and the dialysate 
to initial dialysate glucose concentration ratio (Dt/D0) during a 4-hour dwell period with 
a conventional peritoneal dialysis ﬂ uid. Based on reference values, the transporter state 
of an individual can be characterized as high, high average, low average or low (8). Th e 
disadvantage of the D/P ratio is that it is dependent on the volume used: using a smaller 
test volume will result in a higher D/P ratio, reﬂ ecting a more rapid equilibration of the 
solute between dialysate and plasma but not necessarily enhanced transport capacity (40). 
Th is is explained by the fact that equilibration occurs more rapidly when the dialyzed solute 
diﬀ uses into a relatively small volume. Th e MTAC characterizes the diﬀ usive permeability 
of the peritoneal membrane independent on dialysis mechanics. Th erefore it is better to 
use the MTAC for low molecular weight solutes if you want to compare solute transport 
data in study groups using diﬀ erent test volumes.
Adaptation of the PET allows for calculation of more useful and extensive information on 
transport parameters of the peritoneal membrane. Th e addition of poly-disperse dextran 
70 to the test solution allows for the simultaneous measurement of transcapillary ultraﬁ l-
tration, marker clearance rate, and intraperitoneal volume. Both in adults and in children 
experiences with this modiﬁ ed PET, also called a standard permeability analysis (SPA), 
have been reported.        
Reddingius et al performed PETs in children, using a test volume of 1200 ml/m² and 
1.36% glucose and 3.86% glucose as a test solution (67). Th ey compared the results with 
those obtained in adult patients and did not ﬁ nd any diﬀ erences. Bouts et al used a 1.36% 
glucose solution as a test solution and also did not ﬁ nd essential diﬀ erences between adults 
and children (17).         
Studies performed in adult patients revealed that it is best to perform a peritoneal function 
test with a 3.86% glucose solution because it provides better information on ultraﬁ ltration 
as compared to glucose solutions with lower glucose concentrations (68,69). Solutions 
with a higher osmolarity will provide more information on transcellular water transport 
than those with a low hyperosmolarity (like 1.36% glucose solution) since the latter will 
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hardly induce transcellular water transport (68). It was demonstrated that the use of test 
solutions with diﬀ erent osmolarities do not aﬀ ect solute kinetics, lymphatic absorption 
and the contribution of small pores to peritoneal transport (68). 
Haraldsson was the ﬁ rst to describe the use of the Personal Dialysis Capacity test (PDC) 
as a method of estimating the true peritoneal capacities of individual patients (70). Th is 
method is based on the three-pore model of ﬂ uid and solute transport across the peritoneal 
membrane and was designed to mimic an ordinary dialysis day. Th e PDC is performed 
by the patient him/herself, following a protocol with 5 exchanges in 24 hours using dif-
ferent dwell times and two diﬀ erent glucose solutions. Th e PDC is used to calculate 3 
parameters: 1) the ‘area parameter’ or unrestricted pore area available for exchange over 
the diﬀ usion area (A0/∆X), which is a fundamental physicochemical parameter for trans-
port across porous membranes, determining the diﬀ usion capacities for all solutes, 2) 
‘absorption’ or the reabsorption rate of ﬂ uid from the abdominal cavity to blood, when 
the glucose gradient has dissipated and 3) the ‘large pore ﬂ ow’ representing the ﬂ ux of 
plasma through the large pores (70). In a large multicentre trial it was conﬁ rmed that the 
PDC is a reliable tool for routine evaluation of the peritoneal membrane (71). Th us far 
only one study was undertaken to evaluate the eﬀ ectiveness of PET and PDC in estima-
ting the peritoneal exchange capacity in comparison to one another. It was demonstrated 
that the unrestricted pore area available for exchange over the diﬀ usion area correlated 
much better to the plasma appearance rate of intraperitoneally administered iohexol than 
the PET parameters (72). As iohexol has proven to be a useful marker of the peritoneal 
exchange, or the capillary exchange of solutes during dialysis (73), this study implies that 
A0/∆X is a better indicator of peritoneal membrane function than PET parameters are 
(72). In children limited experience with PDC has been published. Schaefer et al conﬁ r-
med that the PDC test is able to model the individual peritoneal membrane function with 
precision (74). Th ey showed that the test could also be performed in APD patients using 
a simpliﬁ ed study protocol, not requiring a change from an APD to a CAPD regimen, 
without losing its precision and reliability. Th is facilitates the use of a PDC test in most 
pediatric patients (74). More recent data obtained in pediatric patients imply that A0/∆X 
can be estimated adequately from the D/P ratios derived from PET analysis (63). In this 
study experimentally determined D/P or D/D0 concentration ratios for urea, creatinine, 
phosphate, protein and glucose were used to estimate A0/∆X for each individual patient 
by using newly developed computer software (63). Th is implies that routine performance 
of PET, in combination with the use of adapted computer software will be suﬃ  cient to 
evaluate peritoneal membrane function with more precision.
5 Adequacy of peritoneal dialysis
Th ere is an increasing recognition of the inﬂ uence of adequate solute clearance on patient 
outcome in peritoneal dialysis. Studies in adults have suggested that higher clearances of 
small molecules are associated with better survival and lower morbidity (75). As a con-
sequence measurement of peritoneal dialysis eﬃ  ciency is based on the clearance of small 
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solutes like urea and creatinine. 
Current standards suggest the use of a full 24-hour dialysate collection to estimate precisely 
the creatinine clearance (CCr) and the Kt/V urea in automated peritoneal dialysis (76,77). 
A CCr of 63 l/week/1.73 m² and a Kt/V urea of 2.1 have been proposed as adequacy 
targets for a CCPD regimen and a CCr of 66 l/week/1.73 m² and a Kt/V urea of 2.2 for 
a NIPD regimen (78). Th e diﬀ erences in adequacy targets between the diﬀ erent dialysis 
regimens are based on the fact that there is an 8% diﬀ erence in clearance between CAPD 
and NIPD, suggesting that the delivered dose of NIPD would need to be 8% higher than 
the CAPD dose. Subsequently it is assumed that the required dose of CCPD would need 
to be intermediate between those for CAPD and NIPD (78). For children similar ﬁ gures 
have been proposed (79). However it is generally accepted that a CCr > 63 l/week/1.73 
m² is very hard to achieve (7,80,81), especially in anuric patients.
In adult patients mortality is often used as a criterion for dialysis adequacy (82), but it is 
harder to deﬁ ne adequate dialysis in children. Schaefer et al (7) stated that the peritoneal 
transport state is a weak but signiﬁ cant independent determinant of growth and body mass 
acquisition: high transporters were found to be at increased risk for growing poorly and 
becoming obese. Also hospitalization time, metabolic control and the need for medication 
are suggested as measures for clinical outcome (80). Th e sparse data in pediatric patients 
suggest an improvement of clinical outcome under adequacy control (7,80), however the 
number of patients studied and the limited follow-up period in the studies concerned do not 
provide deﬁ nitive evidence. A recent study underlines the importance of critical judgment 
of the use of adequacy control based on creatinine and urea kinetics (83). In a prospective 
randomized study in 965 adult patients it was shown that increases in clearances of urea 
and creatinine did have no eﬀ ect on patient survival at all. Th ese sensational and unexpected 
results presently give rise to reﬂ ection in the peritoneal dialysis world (84‒90).
Beside the use of CCr and Kt/V urea as index of dialysis adequacy, also the use of the solute 
removal index (SRI) has been suggested. Th e SRI is also based on solute removal, but it 
normalizes removal by the solute content of the body at the beginning of the treatment or 
at the beginning of the week: the ratio between net urea removal and the predialysis urea 
body pool is determined (91,92). Th e SRI appeared to be a more reliable index of adequacy 
compared to Kt/V urea in children, since most children are on an intermittent dialysis 
regimen and SRI is independent of the time that the clearance of solutes (or dialysis) is 
applied (93). Further studies will be needed to further explore the usefulness of SRI as a 
tool to measure dialysis adequacy.
Eﬃ  ciency measurement based on creatinine and urea kinetics does not take into account 
the clearance of low molecular weight plasma proteins and the so-called ‘middle molecules’, 
with a molecular weight ranging from 0.3-5 kD. Montini et al demonstrated in pediatric 
patients that there is a progressively increasing peritoneal resistance to the transport of sub-
stances with increasing molecular weight (especially when the molecular weight is ≥ 5 kDa) 
(94). Another study reported an increase of the restriction coeﬃ  cient for macromolecules 
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in relation to time on peritoneal dialysis, which indicates an increased size selectivity or 
a reduced peritoneal permeability for higher molecular weight solutes (17). Th e residual 
renal function seems to play a central role in removing some low molecular weight plasma 
proteins and the ‘middle molecules’ (94). As a consequence patients on peritoneal dialysis 
will have greater diﬃ  culty removing higher molecular weight substances and therefore 
accumulation of many substances will occur, especially in patients with no residual renal 
function. A study in adult patients also showed that as solute molecular weight increases the 
inﬂ uence of decreased daily dialysis time becomes increasingly important (95). Especially 
in children, who often are on a nightly intermittent peritoneal dialysis (NIPD) regimen 
with relatively short dwell times, this seems to be of signiﬁ cance. 
One of the low molecular weight plasma proteins that seem to accumulate in patients on 
PD is leptin. Leptin is a product of fat cells that regulates food intake through modulation 
of satiety signals (96). Recently elevated levels of leptin have been reported in adult and 
pediatric uremic patients, especially in those treated with peritoneal dialysis (97‒99). In 
children an inverse relationship was observed between body mass index-adjusted leptin 
levels and the spontaneous energy intake, which supports the hypothesis that inappropriate 
elevated levels of leptin contribute to decreased nutrient intake (97).
6 Changes in peritoneal permeability
As discussed previously diﬀ usion is the most important transport parameter for low mole-
cular weight solutes. Th e product of the mass transfer area coeﬃ  cient and the concentration 
gradient between blood and dialysis ﬂ uid determines the rate of diﬀ usion. Th e MTAC is 
mainly determined by the so-called eﬀ ective peritoneal surface area, or functional area of 
exchanges between blood and dialysate. 
Th e eﬀ ective peritoneal surface area is determined by two parameters: the amount of 
perfused peritoneal capillaries and the size of the contact area between the peritoneum 
and the intraperitoneal dialysis solutions. Consequently changes in the capillaries, in the 
amount of perfused capillaries and in the size of contact area between the peritoneum and 
dialysis solutions will aﬀ ect the peritoneal permeability. 
6.1 Changes in vascular surface area
6.1.1 Nitric oxide
Several lines of evidence suggest that nitric oxide (NO) is involved in regulation of peri-
toneal transport during peritoneal dialysis. NO is synthesized from L-arginine by a family 
of 3 NO synthase (NOS) isozymes, according to the tissue in which they were initially 
cloned: neuronal NOS , inducible NOS (cloned from macrophages) and endothelial NOS 
(eNOS). Addition of the NO donor nitroprusside to the dialysate increases both the ef-
fective peritoneal surface area and the intrinsic permeability of the membrane in animal 
models (100) and PD patients (101). Long-term PD is associated with a progressive increase 
of NOS activity within the peritoneum, due to upregulation of eNOS, which reﬂ ects 
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neoangiogenesis (102). Th ere was a strong positive correlation between time on PD and 
increase in NOS activity (102). Th e development of a large vascular peritoneal surface area 
was already suggested by the high solute transport rates that have been described in long-
term peritoneal dialysis patients (103,104) and conﬁ rmed by histomorphometric studies 
(102,105). In a rat model of acute peritonitis an increase of NOS activity was seen due to 
upregulation of eNOS and iNOS (106).
6.1.2 Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a heparin-binding growth factor that plays 
a prominent role in physiologic and pathologic angiogenesis (107). As demonstrated in a 
rat model, VEGF is a key mediator in hyperglycemia-induced neoangiogenesis (108,109) 
and also seems to be responsible for inducing and maintaining the baseline permeability 
of the endothelial cells (108). In long-term peritoneal dialysis patients there is a marked 
upregulation of the expression of VEGF (102). In the human peritoneal membrane 
VEGF is localized in the endothelium lining the peritoneal capillaries (102). Th e amount 
of VEGF present in fresh peritoneal eﬄ  uent suggests local production of VEGF in ad-
dition to unknown amounts potentially transported from plasma (110, 111). Relations 
between peritoneal transport parameters and peritoneal eﬄ  uent VEGF levels were found 
by Zweers et al (110) but could not be conﬁ rmed by others (111). Th ere was a lack of 
correlation between VEGF levels and cumulative glucose exposure (111). Recently it was 
demonstrated in rats that octreotide, a long-acting somatostatin analog, is able to protect 
against vascular alterations and preserving peritoneal function by inhibiting overexpression 
of VEGF (109). Although it is clear that VEGF plays a role in peritoneal angiogenesis, it 
is likely that VEGF is integrated in a complex relationship involving multiple peritoneal 
structures and growth factors (102,107, 111, 112). 
6.1.3 Advanced glycation end products
Advanced glycosylation end products (AGEs) are formed as the result of the non-enzy-
matic glycosylation of proteins (113). Th e AGEs that are formed from this reaction can 
irreversibly accumulate on long-lived proteins. Glucose degradation products (GDPs), like 
glyoxal, methylglyoxal and 3-deoxyglucosone induce the advanced glycation of proteins. 
Figure 3 summarizes the chemical reactions leading to the formation of GDPs. Patients 
on peritoneal dialysis are exposed to high concentrations of these GDPs: they are exposed 
to GDPs that originate from the uremic circulation (114‒116) and from the glucose-
based dialysis ﬂ uids in which glucose is converted into GDPs during heat sterilization. 
Consequently there is accumulation of AGEs within the peritoneal membrane (102,112). 
Peritoneal AGE accumulation increases with time on peritoneal dialysis: both prolonged 
use of glucose-containing dialysis solutions and more frequent use of glucose solutions 
with a higher glucose concentration result in higher peritoneal AGE accumulation (117). 
Peritoneal AGE accumulation also increases with increasing number of peritonitis episodes 
(117). Th is might be a consequence of the increased glucose load during peritonitis, used 
to overcome smaller ultraﬁ ltration volumes (22). 
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6.2 Changes in the effective peritoneal surface area
In animal studies it was demonstrated that even with the use of large intraperitoneal volu-
mes the area of contact between dialysis ﬂ uid and the peritoneal membrane is limited to 
approximately 25-30% of the total peritoneal area (56, 118, 119). Determination of the 
proportion of the peritoneal surface area in contact with the dialysis ﬂ uid was performed 
by addition of labeled IgG to a dialysis solution and subsequent analysis of the peritoneum 
of the animal (56). Th e contact area of a dialysis ﬂ uid in the peritoneal cavity was 0.55 
m² in 6 patients (120), implying that 30 to 60% of the anatomic area is wetted during 
peritoneal dialysis in a 70 to 80 kg patient, using a ﬁ ll volume of 2 L (56). Increasing the 
eﬀ ective peritoneal surface area improves the mass transfer of small solutes and thus the 
eﬃ  ciency of dialysis (56,118,119,121‒123). Th ere are several methods of enhancing the 
eﬀ ective peritoneal surface area like increasing the intraperitoneal ﬁ ll volume, adjustment 
of posture and the use of surfactants. In mice it was shown that when given enough time 
in the peritoneal cavity, the ﬂ uid would make contact with most of the peritoneal surface 
(56), presumably through the peristaltic movement of the hollow viscera. It is not likely 
that this slow movement of ﬂ uid through the cavity will increase the contact area through 
which the transfer of solutes will occur. Th e violent maneuvers imposed in animals, that 
actually did aﬀ ect the mass transfer (117,118) are not practical or ethically justiﬁ ed in 
human beings. However the application of low-frequency vibration to the abdominal wall 
for three 20-minutes periods every day also has a considerable eﬀ ect (124). 
Both in adults and children the ﬁ ll volume aﬀ ects the eﬀ ective peritoneal surface area (63, 
125). For children the ‘maximum’ area available for exchange is obtained at a ﬁ ll volume 
Figure 3. Formation of certain glucose degradation products via (a) enolization, 
(b) dehydration, (c) cyclization and (d) C-C-cleavage
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of 1400 mL/m² body surface area (63). Also posture has considerable eﬀ ects. Both in 
adults (126,127) and children (128) the mass transfer of small solutes fell in the standing 
position compared with the supine position. In 6 children the eﬀ ective peritoneal surface 
area decreased with 25% with the patient in the standing position (63).
Th e addition of surfactant to dialysis ﬂ uids might be another possibility of contact area 
enhancement. Dioctyl sodium sulfosuccinate (DSS) increases the mass transfer of small 
solutes in a dose-dependent way (121‒123,129) in animal models. Before human im-
plementation of the use of DSS as a surfactant, extensive studies are needed to further 
investigate toxicity, inﬂ ammatory eﬀ ects and the increased loss of proteins (56,122). Th e 
addition of hyaluronan to dialysis ﬂ uid also leads to changes in peritoneal permeability as 
a result of changes in the hydraulic conductivity of the peritoneal membrane, leading to 
higher net ultraﬁ ltration (30). Th is was already discussed in an earlier paragraph. Again 
extensive studies will be necessary before human implementation.
As DSS is able to restore ultraﬁ ltration by increasing the eﬀ ective area of contact between 
dialysate and the peritoneal membrane, the addition of surface-active phospholipids 
(SAPL) seems to restore ultraﬁ ltration by restoration of membrane semipermeability (130). 
Adsorption of SAPL to peritoneal mesothelium replenishes deﬁ cient lining. Currently 
some clinical trials are running, examining the eﬀ ect of intraperitoneal administration of 
a synthetic SAPL. Th e great advantage of the use of synthetic SAPL is, that it has already 
been used for two decades in the treatment of acute respiratory distress in newborns and 
has proven to be completely safe (130).
7 Innovations in peritoneal dialysis solutions
As a result of the growing awareness of the potential eﬀ ects of the glucose-based, lactate 
buﬀ ered solutions on peritoneal membrane physiology, there is an increasing interest in 
development of more biocompatible dialysis solutions. In spite of all research, glucose is 
still the most widely used osmotic agent in peritoneal dialysis ﬂ uids. Glucose has proven 
to be eﬀ ective and inexpensive, but evidence is growing that continuous exposure to high 
intraperitoneal glucose concentrations has detrimental eﬀ ects on the peritoneal mem-
brane. Th e high glucose concentrations depress proliferation and cytokine production 
of mesothelial cells (131,132). Also the deposition of AGE in the peritoneal membrane 
(112, 133) and the ﬁ ndings of advanced vascular changes typical of diabetes in peritoneal 
biopsy samples (105, 134, 135) are related to the long-term use of high glucose concen-
trations. Th e goal for the clinician is to avoid the pathogenic factors, which are responsible 
for changes in the peritoneal membrane. Th ese factors are: (1) a low pH and lactate and 
glucose itself, through its metabolism via the polyol pathway (136); (2) glucose exposure 
leading to vascular changes of neovascularisation and deposition of type IV collagen in the 
interstitium (105); (3) formation of advanced glycation end products in peritoneal tissue 
(137,138) and (4) the presence of glucose degradation products generated during steam 
sterilization (137,138,139). 
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Th e greater appreciation of the deleterious eﬀ ect of current solutions has led to the deve-
lopment of a large number of solutions that diﬀ er either in buﬀ er, sterilization procedure 
or composition.
7.1 Bicarbonate-buffered dialysis ﬂ uid
Bicarbonate-based PD solutions are buﬀ ered at neutral pH. Th e use of this more physio-
logical buﬀ er can be achieved only if a double bag is created: one side containing glucose 
and calcium, the other containing sodium bicarbonate. Th ese bags have to be mixed shortly 
before administration. Bicarbonate-buﬀ ered solutions have a more physiological pH (7.0-
7.6) than lactate-based solutions (pH 5.5-6.5) (140). Th e solutions currently available are 
entirely bicarbonate or a lactate/bicarbonate mixture. In vitro studies showed markedly bet-
ter preservation of the function of macrophages and peritoneal mesothelial cells (141,142). 
Evidence is not yet available that bicarbonate solutions impart beneﬁ t to patients in terms 
of preserving the peritoneal membrane integrity. Clinical experience in pediatric patients 
has been presented, showing no diﬀ erences in peritoneal mass transport kinetics between 
bicarbonate and lactate buﬀ ered solutions for water and most solutes (143, 144). In the 
PET in pediatric patients both solutions also have similar behavior (145). Th e results of 
a comparative study between the conventional lactate-buﬀ ered and the new bicarbonate-
buﬀ ered solution performed in children suggest that the bicarbonate -buﬀ ered solution 
has a superior clinical tolerance (146). Less inﬂ ow pain induced a lower intraperitoneal 
pressure, and a lower unrestricted pore area available for exchange over the diﬀ usion area 
(A0/∆X) suggesting the occurrence of fewer long-term vaso-active eﬀ ects of the bicarbonate 
buﬀ ered dialysis ﬂ uid. As these results were obtained from a very short-term study, long-
term clinical trials will be needed to conﬁ rm the idea that bicarbonate buﬀ ered dialysis 
ﬂ uids will improve dialysis therapy for children on cchronic peritoneal dialysis. Patients 
who experience pain at infusion of PD ﬂ uid related to pH and lactate have been shown to 
improve dramatically on bicarbonate and bicarbonate/lactate solutions (142,147).
7.2 Double chambered bags
Acetaldehyde is detected as a major glucose degradation product in single-chamber perito-
neal dialysis ﬂ uid bags. Acetaldehyde is formed during heat sterilization, by a mechanism 
that is mediated by glucose (136). Consequently separation of glucose and lactate during 
heat sterilization by the use of a double-chamber bag inhibits the formation of acetaldehyde 
(136). Separation of glucose from other solution components also allows for glucose to 
be sterilized at a lower pH than is possible in single-chamber bags. It has been shown that 
the low pH in the glucose compartment (especially in a pH range between 2.5 and 3.5) 
considerably lowers glucose degradation (136). Until now there have been no biological 
function data or clinical outcome studies supporting the idea that double-chamber bags are 
superior to single-chamber bags. However glucose degradation products are known to be a 
precursor of AGEs, which implies that double-chamber bags with low glucose degradation 
products levels will be favorable to peritoneal membrane integrity. 
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7.3 Icodextrin
Icodextrin is mainly characterized by the absence of glucose. Instead long-chain glucose 
polymers are present which are responsible for the ultraﬁ ltration. Th e commercially avai-
lable 7.5% glucose polymer solution, icodextrin, contains a polydisperse solution of starch 
derived glucose polymers with a mean molecular weight of 16.800 Da and a pH of 5.2-5.6. 
Icodextrin is capable of inducing an osmotic ﬂ ow across the peritoneal membrane, even 
though the solution is iso-osmolar to plasma (284 mOsm/kg). Ultraﬁ ltration occurs ac-
cording to the principle of colloid osmosis, meaning that there is a ﬂ uid ﬂ ow across a semi-
permeable membrane in the direction of the relative excess of large molecules (148).
Extensive long-term clinical experience with icodextrin in adults has been reported 
(66,149‒153). Th e solution induces a slow but sustained ultraﬁ ltration for up to 16 hours 
in automated peritoneal dialysis (148,149,153) and the ultraﬁ ltration volume obtained after 
a long-term dwell is similar to the ultraﬁ ltration volume obtained with a 3.86% glucose 
solution (149,153). Clinical studies show that icodextrin is especially eﬀ ective during long-
term dwells and in patients with ultraﬁ ltration failure due to a large eﬀ ective peritoneal 
surface area (154‒157). Also computer modeling suggests that icodextrin will produce an 
increased ultraﬁ ltration rate in patients with an increased eﬀ ective vascular surface area 
(66). Icodextrin has proven to be able to preserve the daytime dwell ultraﬁ ltration during 
peritonitis, when glucose often fails as osmotic agent due to increased glucose absorption 
(158) and both ﬂ uid and blood pressure control improve with the use of a daytime dwell 
with icodextrin (159). One study performed in 21 adult patients demonstrated a beneﬁ cial 
eﬀ ect of icodextrin use on lipid proﬁ les (160), which is one of the major risk factors for 
cardiovascular complications. 
Several studies have been published concerning the side eﬀ ects of icodextrin. Th e main 
side eﬀ ect of icodextrin use has been skin rashes, which were documented both in adults 
(161‒164) and in children (165). Another side eﬀ ect of icodextrin use is the occurrence 
of icodextrin induced sterile peritonitis (166‒168). Patients present with cloudy dialysate, 
no or mild abdominal pain, a variable cell count with a variable percentage of neutrophils, 
monocytes, eosinophils and lymphocytes, dialysate cultures remain negative, and com-
plaints disappear after discontinuation of icodextrin. For a long time the pathogenesis of 
these peritonitis episodes was not clear, and hypersensitivity to icodextrin seemed to be 
the most likely cause. However extensive investigations revealed that the problems are 
probably due to contamination of some batches of icodextrin with a peptidoglycan, which 
is a non-endotoxin weak pyrogen capable of provoking inﬂ ammatory responses (169). 
In these cases of sterile peritonitis icodextrin should be stopped. If the eﬄ  uent becomes 
clear after discontinuation of icodextrin, it seems worth trying icodextrin from a diﬀ erent 
batch. But if on icodextrin rechallenge the complaints recur, then icodextrin should not 
be prescribed again, and hypersensitivity for icodextrin should be considered.
Icodextrin exerts no long-term toxicity. Its use is accompanied with a rise in plasma oli-
gosaccharides, but no clinical adverse events have been related thus far. Oligosaccharide 
levels return to baseline after ending treatment (151, 165). Several ex vivo studies have 
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demonstrated improvement in both peritoneal and mesothelial cell function in patients 
using icodextrin-based dialysis solutions for one exchange per day while using conventional 
solutions for the other exchanges (170,171). In addition the use of icodextrin decreases the 
formation of advanced glycation end products (172,173), but in combination with night-
time exposure to glucose there is no decrease of eﬄ  uent levels of glycation end products 
observed (173). It was also demonstrated that the use of icodextrin is accompanied with 
a decrease in the eﬄ  uent concentration of reactive carbonyl compounds (which generate 
advanced glycation end products) as compared to the conventional heat-sterilized glucose 
solutions (174). However some doubts about the safety of icodextrin have been raised fol-
lowing the results of an in vivo study in mice suggesting that icodextrin induces substantial 
DNA injury through a mechanism of lipid peroxidation (175). Also long-term use of 
icodextrin in rats was shown to induce increases in peritoneal protein excretion, although 
transport of small solutes was not aﬀ ected (176). Further studies are needed to elucidate 
these negative eﬀ ects of icodextrin in humans. 
In contrast with the extensive amount of experiences with icodextrin reported in adult 
patients, thus far only one study has been published reporting experiences with icodextrin 
in pediatric patients (165). It was demonstrated that the addition of a daytime icodextrin 
dwell to a NIPD regimen with conventional glucose solutions results in an increase of 
ultraﬁ ltration and gives an increase of the weekly Kt/V urea of 0.52. Th e metabolism of 
icodextrin is similar to that in adults, implying an increase of serum oligosaccharides mal-
tose, maltotriose and maltotetraose, reaching a steady state level after approximately two 
weeks and followed by a decrease to baseline levels after stopping treatment. Th is study 
also demonstrated that icodextrin is capable of inducing a sustained ultraﬁ ltration for up to 
12 hours and the ultraﬁ ltration volume after 12 hours is comparable to the ultraﬁ ltration 
volume obtained with a 3.86% glucose solution (165). In chapter 1 the eﬀ ect of icodextrin 
on solute and ﬂ uid kinetics in children will be discussed and a comparison is made with 
the transport characteristics of icodextrin obtained in adult patients (66).
8 Intraperitoneal drug administration
Th e main objective during peritoneal dialysis in children is the removal of excess body 
water and waste products, using the peritoneal membrane as a ﬁ lter. However once a per-
manent catheter into the peritoneal cavity is present, it allows for usage of the peritoneal 
cavity as a pathway of drug application. Th is administration route can be advantageous 
in cases of intravenous access problems, treatment of infections or malignancies localized 
to the peritoneal cavity but it can also be very well applied to treat systemic diseases like 
diabetes. In pediatric peritoneal dialysis special attention must be paid to the psychosocial 
advantage of intraperitoneal drug administration, especially when intraperitoneal admi-
nistration can avoid the use of the subcutaneous injections. Subcutaneous administration 
of drugs is painful and distressing for both the child and his or her caregivers. Studies 
on the compliance with the subcutaneous administration of growth hormone reveal that 
noncompliance varies between 50 and 91% (177‒179). In adult patients a noncompliance 
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with subcutaneous administration of erythropoietin was reported for 35% (180) and 55% 
of the patients (181). Independent predictors of noncompliance are reported to be younger 
age, completion of postsecondary education and missing dialysis exchanges (180).
8.1 Erythropoietin
Th e pharmacological development of human recombinant erythropoietin has been a major 
development in the treatment of renal anemia. Th is hormone is normally produced by a 
ﬁ broblast-like cell population in the cortical interstitium of the kidney and induces pro-
liferation and diﬀ erentiation of erythroid progenitor cells in the bone marrow, resulting 
in an increase in circulating red blood cells. Anemia in patients with chronic renal failure 
is an important clinical problem, aﬀ ecting over 90% of patients. Th e anemia is primarily 
caused by a decreased production of erythropoietin by the diseased kidney (182) but is 
also caused by a decreased red blood cell survival (183) and a decreased response to ery-
thropoietin (184). 
Since the introduction of recombinant human erythropoietin numerous studies have 
demonstrated the eﬀ ectiveness of erythropoietin in preventing and treating renal anemia 
in patients with chronic renal failure, which subsequently decreased the need of blood 
transfusions. Both American (185) and European (186) best practice guidelines are avai-
lable for the management of anemia in chronic kidney disease, however they pay hardly 
any attention to pediatric patients. 
In pediatric dialysis most experiences have been obtained with subcutaneous administration 
of recombinant human erythropoietin (187,188). However despite some initial discouraging 
but still frequently cited reports (189,190) recombinant human erythropoietin can be very 
well administered by the intraperitoneal route. Good absorption of erythropoietin from the 
peritoneal cavity was observed in an animal model, if erythropoietin was administered in 
a small amount of dialysis ﬂ uid (191) and this was conﬁ rmed for humans (192). Th e ﬁ rst 
positive results using intraperitoneal erythropoietin were described in adult patients (193). 
Subsequently it was demonstrated in pediatric peritoneal dialysis patients that, if administered 
in a small amount of dialysis ﬂ uid (50 mL), the bioavailability of erythropoietin is similar 
to that after subcutaneous administration (194). A study performed in a small group of 
children showed that the dosage needed for intraperitoneal administration is similar to the 
dosage needed with subcutaneous administration if the hormone is administered in 50 mL 
of dialysis ﬂ uid (195). In chapter 3 we will conﬁ rm these results in a larger patient group.
Th e major concern using the intraperitoneal administration route is dialysis adequacy, since 
the hormone has to be administered in a very small amount of dialysis ﬂ uid, not allowing 
a regular dwell at the same time. However if adequacy targets can be reached without the 
need of daytime dwells, as in most children treated by NIPD, the intraperitoneal admi-
nistration should be the preferred mode of administration. Guidelines concerning the 
management of anemia in pediatric patients have been published (196).
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Recently Casadevall et al reported the development of pure red-cell aplasia during tre-
atment with recombinant human erythropoietin in adult patients, which worsened the 
initial anemia and made all patients dependent on blood transfusions (197). In all patients 
neutralizing antibodies against erythropoietin were detected. Currently a worldwide dis-
cussion is ongoing concerning the management of this major side eﬀ ect of erythropoietin 
treatment (198‒202).
8.2 Antibiotics
Peritonitis remains one of the major complications of peritoneal dialysis both in adults (75) 
and in children (203,204). Treatment with intraperitoneal antibiotics is generally prefer-
red as this route may be more eﬀ ective than the intravenous or oral route and also results 
in the highest local antibiotic levels (205). Especially in children, who will be dependent 
on their peritoneum for prolonged periods of time, it is important to provide the highest 
eﬃ  cacy of treatment in combination with a low potential of side eﬀ ects like ototoxicity 
and nephrotoxicity. 
Th ere are many published antibiotic regimens for the treatment of peritonitis in perito-
neal dialysis. In an eﬀ ort to standardize the treatment of peritonitis in peritoneal dialysis 
patients, the Advisory Committee on Peritoneal Management of the International Society 
for Peritoneal Dialysis established guidelines (206). Th ese guidelines recommended the 
intraperitoneal use of a combination of a ﬁ rst-generation cephalosporin and an aminogly-
coside. Th e guidelines have been periodically updated as new information became available 
(207‒209). Th e most recent edition of the guidelines advocates the use of a combination 
of a ﬁ rst-generation cephalosporin (cephalotin or cephazolin) and a third-generation cep-
halosporin (ceftazidime) (209). Th ese recommendations are meant for adult patients in 
the ﬁ rst place but have also been followed for pediatric patients. However recently separate 
pediatric guidelines were published (210). Th ey recommend the use of a combination of a 
glycopeptide and ceftazidime, a combination that also has been advocated by the guidelines 
for adults published in 1993 (207), but which was abandoned because of the increasing 
concerns about the risk of the occurrence of multi-resistant microorganisms due to the 
widespread use of vancomycin (208). As the administration of glycopeptides in children 
carries the same risks as in adults, their use should be restricted to selected patients. In 
chapter 4 we present our experiences with the use of a combination of a ﬁ rst- and a third-
generation cephalosporin in unselected patients. 
Aim and outline of this thesis
Peritoneal dialysis takes an important place as a treatment modality for children with chronic 
renal failure. Th is dialysis modality has important advantages compared to hemodialysis: 
it allows children of all ages to receive dialysis at home with the subsequent experience of 
a more normal childhood, and avoids repeated needle punctures other than those needed 
for drug administration. On the contrary this treatment modality places a signiﬁ cant 
burden both on the child and his or her caregivers. Peritoneal dialysis also implies that 
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attention has to be paid to the functionality of the peritoneal membrane, because most 
children will depend on it for a major part of their life. Th erefore the aim of the studies 
presented in this thesis, was to evaluate several issues that might be of use in decreasing 
the psychosocial and physical burden. An attempt was made to study the ﬂ uid kinetics 
of a more biocompatible, glucose polymer based dialysis solution. Furthermore attention 
was paid to diminish the need of subcutaneous drug administration and to avoid the 
toxic eﬀ ects caused by antibiotic treatment of peritonitis. Gastric emptying was studied 
to obtain more insight in gastro-enterological complications of peritoneal dialysis and the 
non-invasive treatment of peritoneal dialysis catheter obstruction and leakage of dialysis 
ﬂ uid was evaluated.
An overview of the current knowledge on peritoneal dialysis in children is described in the 
General Introduction. Th e current knowledge on peritoneal solute and ﬂ uid transport is 
summarized and several factors changing peritoneal permeability are discussed. Experiences 
with intraperitoneal administration of drugs are described brieﬂ y and attention is paid to 
the glucose polymer based dialysis solution icodextrin.
In Part II peritoneal fluid kinetics with the use of icodextrin and the influence 
of diﬀ erent osmotic agents on intraperitoneal pressure are presented.   
Chapter 1 describes the assessment of peritoneal transport characteristics using the glu-
cose polymer based dialysis solution icodextrin. A comparison is made with ﬂ uid kinetics 
using 3.86% glucose solution and results are compared with results obtained in adults. 
In Chapter 2 reference values of the intraperitoneal pressure in children are obtained and 
the Peritoneal Equilibration Test was applied to evaluate the inﬂ uence of diﬀ erent dialysis 
ﬂ uids on the intraperitoneal pressure.
In Part III experiences with the intraperitoneal administration of diﬀ erent drugs are presented.
Chapter 3 investigates the maintenance dosage needed when erythropoietin 
is administered intraperitoneally instead of subcutaneously.    
In Chapter 4 the eﬀ ectiveness of the use of a combination of a ﬁ rst- and a third-generation 
cephalosporin for the initial treatment of peritonitis is studied.  
Finally Part IV concerns some important complications of peritoneal dialysis.  
In Chapter 5 an attempt is done to gain more insight into the gastroenterological com-
plications of children treated with peritoneal dialysis.    
Chapter 6 describes experiences with the use of urokinase in treating peritoneal dialysis 
catheter obstruction.        
Chapter 7 presents the results of the use of ﬁ brin glue in catheter leakage in acute peri-
toneal dialysis.
Finally Part V contains a general discussion and Part VI contains a summary, a summary 
in Dutch and a summary for readers unknown to the subject in Dutch.
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Abstract
Scarce data are available on the use of glucose polymer based dialysate in children. Th e 
eﬀ ects of glucose polymer based dialysate on peritoneal ﬂ uid kinetics and solute transport 
were studied in pediatric patients on chronic peritoneal dialysis and a comparison was made 
with previously published results in adult patients. In 9 children 2 peritoneal equilibration 
tests were performed using 3.86% glucose and 7.5% icodextrin as a test solution. Dextran 
70 was added as a volume marker to calculate ﬂ uid kinetics. Serum and dialysate samples 
were taken for determination of urea, creatinine, and sodium. After calculation of the initial 
transcapillary ultraﬁ ltration rate it was possible to calculate the contribution of aquaporin 
mediated water transport to ultraﬁ ltration for icodextrin and 3.86% glucose and the part of 
LpS (the product of the peritoneal surface area and the hydraulic permeability) caused by 
aquaporins. In children the transport parameters were similar for the two solutions, except 
for transcapillary ultraﬁ ltration (TCUF) which was lower for icodextrin (0.9 ml/min/1.73 
m²) as compared with 3.86% glucose (4 ml/min/1.73 m²). Transport parameters were 
similar in children and adults for glucose, but with icodextrin TCUF and marker clearance 
were signiﬁ cantly lower in children. Aquaporin mediated water ﬂ ow was 83 versus 50% 
with glucose (child versus adult) (P<0.01) and 18 versus 7% with icodextrin (P<0.01). 
Data indicate that transport parameters in children using icodextrin are similar to glucose 
except for TCUF. Diﬀ erences are explained by the absence of crystalloid osmosis and the 
fact that TCUF was determined after a 4-hour dwell. Comparison of transport parameters 
and peritoneal membrane characteristics reveal that there seem to be diﬀ erences in the 
amount and functionality of aquaporins between pediatric and adult patients. However 
there are no diﬀ erences in clinical eﬃ  cacy of this transport pathway since the absolute ﬂ ow 
through the aquaporins is identical in both groups using 3.86% glucose.
Keywords: 
Icodextrin, 3.86% glucose, ﬂ uid kinetics, solute transport, aquaporin, peritoneal dialysis. 
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Introduction
Icodextrin contains glucose polymers as osmotic agent instead of glucose in the conventional 
peritoneal dialysis solutions. Th e eﬀ ectiveness of icodextrin as a colloid osmotic agent has 
been very well established in adult patients (1-4). Th e solution is especially indicated in 
situations where a high exposure to glucose should be avoided such as in patients with 
exchanges with a long dwell time and in patients with ultraﬁ ltration failure (5).
Until now very little has been published about the use of glucose polymer based dialysate 
in children. It was demonstrated that 7.5% icodextrin is capable of inducing sustained net 
ultraﬁ ltration during long term dwell in children and that the metabolism of icodextrin 
is similar compared to adults (6). Th e aim of the present study was to compare a 7.5% 
icodextrin based dialysis solution with a 3.86% glucose solution with regard to peritoneal 
ﬂ uid kinetics and solute transport in a pediatric peritoneal dialysis population. Addition-
ally the results obtained in children were compared with results obtained in adult patients, 
which were previously published (5). A brief summary of the study in adult patients will 
be given in the Methods section.
Methods
Pediatric study 
Th e patient group consisted of 4 girls and 5 boys, with a median age of 4.9 years (range 
1.6 – 10.9). Th e mean duration of nightly intermittent peritoneal dialysis treatment was 
26.2 months (range 5.6 – 122.3). In each patient 2 Peritoneal Equilibration Tests were 
performed, using a diﬀ erent test solution for each Peritoneal Equilibration Test. Th e solu-
tions used were a 7.5% icodextrin solution (Extraneal®, Baxter B.V. Utrecht, Th e Neth-
erlands) and a 3.86% glucose solution (Dianeal®, Baxter B.V. Utrecht, Th e Netherlands). 
All Peritoneal Equilibration Tests were performed as previously described by Reddingius 
et al (7). An intraperitoneal volume of 1200 mL/m2 body surface area (BSA) was used 
in all tests. Dextran 70 (Macrodex NPBI, Emmercompascuum, Th e Netherlands) was 
added to the dialysate as a volume marker to calculate ﬂ uid kinetics. A serum sample was 
taken at the start of the study. Dialysis ﬂ uid was sampled before inﬂ ow, after 5, 30, 60, 
120, 180 minutes and at the end of the test at 240 minutes. Th ese samples were used for 
measurement of dextran, glucose, creatinine, urea and sodium. All Peritoneal Equilibra-
tion Tests were performed at least two months after any peritonitis episode. None of the 
patients had ultraﬁ ltration failure. 
Calculations
For the calculations the principles of Nolph et al. were applied (8), adapted by Krediet et 
al. (9). Transport parameters were calculated according to previously described formulas 
(7). In brief transcapillary ultraﬁ ltration (TCUF) was calculated from the dilution of the 
volume marker, by subtracting the initial theoretical intraperitoneal volume (IPV) from 
the theoretical IPV. Th e theoretical IPV is the IPV in the absence of marker clearance and 
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sampling, in which marker clearance equals the disappearance of ﬂ uid from the peritoneal 
cavity. Th e initial TCUF for the glucose solution and the icodextrin solution, meaning 
the TCUF during the ﬁ rst minute of a dwell (TCUF0-1min) were calculated according to 
the Lineweaver-Burk plot for the glucose-based solution and by linear regression for the 
icodextrin-based one (9). Th e transcapillary ultraﬁ ltration rate (TCUFR) was obtained by 
dividing TCUF by the dwell time.
Th e change in IPV (∆-IPV) was obtained by calculating the dilution of the volume marker 
after correction for incomplete recovery. Th e net ultraﬁ ltration rate was obtained by di-
viding ∆-IPV by the dwell time. Marker clearance was deﬁ ned as the diﬀ erence between 
the amount of dextran instilled and the total amount recovered, divided by the product 
of dwell time and the mean dextran concentration. Marker clearance rate was calculated 
by dividing marker clearance by the dwell time. It was assumed that marker clearance is a 
linear process. Th e mass transfer area coeﬃ  cient (MTAC) is the maximal theoretical dif-
fusive clearance of a solute at time 0, before transport has actually started. Th e MTAC of 
urea and creatinine were calculated according to the Waniewski model (10), in which a 
correction for plasma water concentrations was used (5).
Th e dialysate / plasma ratio of sodium was used to analyze the sieving of sodium dur-
ing the ﬁ rst hour of the dwell for the 3.86% glucose and the 7.5% icodextrin Peritoneal 
Equilibration Test.
Glucose induces ultraﬁ ltration by increasing the crystalloid osmotic pressure in the peri-
toneal cavity, which induces ﬂ uid transport across the small interendothelial pores and 
also through the ultrasmall transcellular pores (aquaporins). Th e eﬀ ect of glucose on the 
large pores can be neglected because of their very small number and large pore size. Th e 
colloid osmotic pressure induced by icodextrin almost exclusively exerts its eﬀ ect across 
the small pores. Th is implies that the ultraﬁ ltration coeﬃ  cient (UFC) of the transcellular 
pores (UFCaqp) can be calculated from the diﬀ erence between the total UFC (UFCtot) 
of the peritoneum, as calculated with 3.86% glucose, and the UFC of the small pores 
(UFCsp), as calculated with icodextrin:
  UFCaqp = UFCtot – UFCsp  
Th e UFC was calculated as previously described by Ho-Dac-Pannekeet et al. (5). A descrip-
tion of the calculations is given in appendix A. 
Th e UFC is the product of the hydraulic permeability of the peritoneum (Lp) and the 
surface area (S). After calculation of the contribution of the transcellular pores to UFCtot, 
it is possible to calculate the fractional transcellular UFC, meaning the part of LpS that 
is caused by AQPs. Subsequently it is possible to calculate the fractional osmotic force 
exerted across the AQPs. Calculations of the fractional transcellular UFC and the fractional 
osmotic force across AQPs were performed using the formulas described by Krediet et al. 
(11). A description of the calculations is given in appendix B. Calculations of the fractional 
transcellular UFC and the fractional osmotic force across aquaporins were also performed 
for the adult patient group.
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Statistical analyses
Results are given as mean and median values, SD and ranges. For comparison of the results 
of the two solutions within the pediatric group, a paired Student-t test was performed. Dif-
ferences between children and adults were tested with the Mann-Whitney nonparametric 
rank test. Correlations were tested using the Spearman rank correlation analysis.
Study in adult patients
Ho-Dac-Pannekeet et al. previously published a study about peritoneal transport charac-
teristics with icodextrin performed in adults (5). Results obtained in this study were used 
(with kind permission of Ho-Dac-Panekeet et al.) to make a comparison with the results 
of our study, which was performed in children. Th e patient group of Ho-Dac-Pannekeet 
et al. consisted of 10 stable patients, with a median age of 48 years (range 23-64). Th e 
mean duration of CAPD treatment was 28 months (range 3-92). In each patient 3 perito-
neal equilibration tests were performed, using a diﬀ erent test solution for each peritoneal 
equilibration test. Th e three test solutions consisted of 1.36% glucose, 3.86% glucose 
and 7.5% icodextrin. Th e peritoneal equilibration test was standardized in the same way 
as in the pediatric study. Dialysate samples were taken at 10, 20, 30, 60, 120, 180 and 
240 minutes. Blood samples were drawn at the beginning and at the end of the period. 
In the glucose dwells dextran 70 was added as a volume marker, whereas in the icodextrin 
dwell dextrin itself was used for that purpose. Calculations of transport parameters were 
made based on the same principles as those used in the pediatric study. Calculations of 
the fractional transcellular UFC and the fractional osmotic force across aquaporins were 
not part of the adult study.
Results
Th e medians and ranges of ﬂ uid and solute transport parameters of children and adults 
obtained with 3.86% glucose and 7.5% icodextrin are given in Table 1. All data are ex-
pressed per 1.73 m² body surface area.
Fluid transport 
Th e TCUFR with icodextrin was signiﬁ cantly lower compared to the TCUFR obtained 
with glucose 3.86% in our study group (P < 0.001). Th e marker clearance rate, and net 
ultraﬁ ltration rate were similar for the two solutions. Fluid proﬁ les for 3.86% glucose and 
7.5% icodextrin are given in Figure 1.
Transport parameters for ﬂ uid transport using 3.86% glucose were similar for children 
and adults. For 7.5% icodextrin the TCUFR in children was signiﬁ cantly lower than in 
adults (p < 0.01). Also the marker clearance rate was signiﬁ cantly lower (p<0.02). Th e net 
ultraﬁ ltration rate however was not signiﬁ cantly diﬀ erent from adult patients (p = 0.27). 
Consequently the ∆-IPV was also similar for children and adults (p = 0.36). 
Solute transport
Th e transport of the low molecular weight solutes creatinine and urea in children was 
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3.86% Glucose 7.5% Icodextrin
Median range Median range
MTACurea  ml/min/1.73 m²
Child 15.4 11.9-21.2 24.9 17.6-24.9
Adult 19.1 12-27 14.1 6-26
MTACcreat  ml/min/1.73 m²
Child 9.3 6.4-10.9 8.6 5-13.8
Adult 11.7 6-21 14.3 7-24
TCUFR  ml/min/1.73 m²
Child 4.0 1.6-5.4 0.9 0.5-1.9a ,b
Adult 4.5 0.5-6.4 2.3 1.4-4.8
MCR  ml/min/1.73 m²
Child 1.3 0.1-10.8 0.4 0-2.0c
Adult 1.0 0.2-4.4 1.1 0-6.8
NUFR ml/min/1.73 m²
Child 3.0 -9.3-4.2 0.2 -1.6-1.8
Adult 3.2 -1.5-5.1 1.1 -2-2.3
∆-IPV ml/1.73 m²
Child 715.8 -224.2-1006.6 52.1 -394.6-443.3
Adult 724 -274-1127 227 -437-527
Time on PD months
Child 12 5.6-122.3
Adult 28 3-92
D/P creatinine
Child 0.57 0.52-0.83 0.61 0.41-0.63
Table 1. Comparison of ﬂ uid and solute transport parameters in children and adults during 
a 4-hour dwell with 3.86% glucose and 7.5% icodextrin.
Adult data are obtained from a previously published study (5). Mass transfer area coeﬃ  cient 
of urea (MTACurea), mass transfer area coeﬃ  cient of creatinine (MTACcreat), transcapil-
lary ultraﬁ ltration rate (TCUFR), marker clearance rate (MCR), net ultraﬁ ltration rate 
(NUFR), ∆-intraperitoneal volume (∆-IPV) and D/P creatinine (dialysate/plasma ratio 
creatinine). Statistical analysis was performed with Mann-Whitney nonparametric test. 
a p<0.01 3.86% glucose versus icodextrin
b p<0.01 children versus adults 
c p=0.02 children versus adults
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      A
      B
Figure 1. Changes of intraperitoneal volume (ml/1.73 m²) in time. Transcapillary ultra-
ﬁ ltration (♦), marker clearance () and net ultraﬁ ltration () during a 4-hour dwell 
in children using 7.5% icodextrin (A) and 3.86% glucose (B). TCUF after 4 hours was 
signiﬁ cantly lower during the icodextrin Peritoneal Equilibration Test (p<0.01). Ultraﬁ ltra-
tion and marker clearance after 4 hours were similar for 3.86% glucose and icodextrin.
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similar for both solutions. A correlation was found between net ultraﬁ ltration rate and 
MTACcreat (r=0.69, p<0.04) in the icodextrin dwell, which was not found in the glucose 
dwell. No relation was found between MTACcreat and age or time on PD. 
No signiﬁ cant diﬀ erences were found between children and adults. A marked dip in dialy-
sate / plasma ratio of sodium was found in the initial phase of the 3.86% glucose dwell, 
which was absent in the dwell with the icodextrin solution (Figure 2).
Contribution of the aquaporins to the peritoneal ultraﬁ ltration coefﬁ cient
Th e mean UFCtot calculated with 3.86% glucose solutions was 0.12 ± 0.002 ml/min/mm 
Hg. Th e AQPs contributed 83.4 ± 6.4% to this value. In the adult patient group the 
AQPs contributed 50.5 ± 12% to a mean total UFC of 0.18 ± 0.04 ml/min/mm Hg (P 
< 0.01). Th e mean UFCaqp in children was 0.10 ± 0.02 ml/min/mm Hg and 0.12 ± 0.10 
ml/min/mm Hg in adults (P = 0.64)
Both in children and adults there was no signiﬁ cant correlation between the UFCaqp and 
duration of PD treatment (children r = 0.58, NS; adults r = -0.56, NS) , or age (children 
r = -0.12, NS); adults r = 0.19, NS). 
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Figure 2: Dialysate / plasma ratios of sodium during 4-hour dwells with 3.86% glucose () 
and 7.5% icodextrin () in children (solid lines) and for 3.86% glucose () and 7.5% 
icodextrin (∆) in adults (dotted lines). Th e dialysate sodium concentration decreases with 
3.86% glucose because aquaporin mediated water transport exceeds the eﬀ ect of sodium dif-
fusion. Icodextrin induced no changes in dialysate / plasma sodium.
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Th e mean fractional transcellular UFC calculated using 3.86% glucose was 0.15 ± 0.06 
mL/min/mm Hg in children and 0.05 ± 0.04 mL/min/mm Hg in adults (P < 0.001) 
which implies that the AQPs are responsible for respectively 15% and 5% of the LpS. Th e 
fractional transcellular UFC in children showed a signiﬁ cant negative correlation with 
the duration of PD treatment (r = -0.67, P < 0.05) but showed no correlation with age (r 
= 0.13, NS). In adults there was no signiﬁ cant correlation with duration of treatment or 
age. Th e mean fractional osmotic force exerted across AQPs using 7.5% icodextrin was 
0.18 ± 0.07 mL/min/mm Hg in children and 0.07 ± 0.06 mL/min/mm Hg in adults (P 
< 0.001), implying that respectively 18% and 7% of the water ﬂ ow occurs through the 
AQPs during a dwell with icodextrin.
Discussion
During the last ten to ﬁ fteen years there is a growing recognition of the need for the 
development of dialysis solutions, which are more biocompatible than the standard 
commercially available glucose based solutions. Icodextrin is mainly characterized by the 
absence of glucose. Instead long-chain glucose polymers are present which are responsible 
for ultraﬁ ltration. Ultraﬁ ltration occurs according to the principle of colloid osmosis. Th e 
absorption of glucose polymers is limited which gives rise to a prolonged persistence of 
the colloid osmotic gradient. Th e use of icodextrin has been extensively studied in adult 
patients. It has been shown that the daily use of icodextrin is safe, generally well tolerated 
and it can replace the daily overnight use of hyperosmotic glucose solutions (2,3). Posthuma 
et al. demonstrated that icodextrin could also be very well used in an automated peritoneal 
dialysis regimen to enhance ultraﬁ ltration during the long daytime dwell (12). Th e use of 
icodextrin is associated with a signiﬁ cant increase in serum concentrations of icodextrin 
metabolites, which however has not been associated with clinical adverse events (3,12).
Until know very little is published about the use of glucose polymer based dialysate in 
children. In a previous study it was demonstrated that the addition of a daytime icodextrin 
dwell to a Nightly Intermittent Peritoneal Dialysis regimen in children results in an increase 
of both ultraﬁ ltration and adequacy of dialysis and that the metabolism of icodextrin occurs 
at a similar rate compared to that in adults (6). However there are no data available with 
respect to the eﬀ ect of icodextrin on the peritoneal ﬂ uid kinetics and solute transport. Th e 
present study describes the behavior of icodextrin in the peritoneal equilibration test in 
children and compares the results with previously published data obtained in adults (5). 
Th e values of ﬂ uid transport parameters with 3.86% glucose found in the present study, 
were within the ranges of those found in a previous study performed in pediatric patients 
(13). Th e transcapillary ultraﬁ ltration with icodextrin was diﬀ erent from that obtained 
with 3.86% glucose. Th is can be explained by the fact that ultraﬁ ltration was measured 
after a 4-hour dwell time; 3.86% glucose gives rise to a rapid ultraﬁ ltration in the begin-
ning of the dwell which diminishes in time because of dissipation of the osmotic gradient, 
whereas icodextrin gives rise to a slow but sustained ultraﬁ ltration during a prolonged 
period because of the limited absorption of the glucose polymers (14). 
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Icodextrin in children
Fluid kinetics for 3.86% glucose are similar in children and adults. Th is is in accordance 
with a previous study that showed that ﬂ uid kinetics in diﬀ erent age groups are comparable 
if corrected for body surface area (13,15). Based on these observations it is expected that 
ﬂ uid kinetics for icodextrin are also similar between the diﬀ erent patient groups. Results 
previously published by the Boer et al. already showed that net ultraﬁ ltration obtained 
with icodextrin is similar for children and adults after a long term dwell (6). However our 
results are not fully in accordance with the expectations. Net ultraﬁ ltration is similar for 
both groups, but transcapillary ultraﬁ ltration and marker clearance are signiﬁ cantly lower 
in children. Rippe et al. demonstrated an advantage of using icodextrin in patients with an 
increased eﬀ ective vascular area, because icodextrin will produce an increased ultraﬁ ltration 
rate when the vascular surface area is increased (16). Th e diﬀ erence in transport parameters 
using icodextrin between adults and children may thus be explained by a diﬀ erence in 
eﬀ ective vascular surface area. Although a statistical diﬀ erence in treatment period is not 
present, there seems to be an overrepresentation of long-term dialysis in the adult patient 
group. Long-term dialysis is associated with neoangiogenesis in the peritoneum (17-19) 
which can explain an increase in the eﬀ ective peritoneal surface area. However there was 
no signiﬁ cant diﬀ erence in MTACcreat, which indicates that there is no diﬀ erence in the 
eﬀ ective peritoneal surface area. Due to the small sample of patients we also have to realize 
that statistical comparison is easily bothered by chance observations. Based on these results 
it is therefore not possible to give an explanation for the diﬀ erences seen in marker clear-
ance and transcapillary ultraﬁ ltration. As the net ultraﬁ ltration is similar for children and 
adults it is most likely that in clinical practice there are no diﬀ erences to be expected.  
Osmotic effect of icodextrin on the peritoneal membrane 
Based on the three-pore model of peritoneal transport suggested by Rippe et al (20,21) 
the aquaporins play a minor role in transcapillary ultraﬁ ltration when using icodextrin but 
a major role in transcapillary ultraﬁ ltration when using 3.86% glucose. Th is is demon-
strated by the signiﬁ cant diﬀ erence in contribution of aquaporins using 3.86% glucose or 
icodextrin in both children and adults. Th is diﬀ erence can be visualized by analyzing the 
diﬀ erence in sodium sieving during the ﬁ rst hour of a dwell. As the water ﬂ ow through the 
aquaporins will exceed the ﬂ ow of water and small solutes through the small pores using 
3.86% glucose, it will cause a fall in the sodium dialysate concentration. Using icodextrin 
there will be no fall in sodium dialysate concentration. In the present study this diﬀ erent 
role of the aquaporins is very well visualized. Using 3.86% glucose the dialysate / plasma 
ratio of sodium decreased, whereas using icodextrin the dialysate / plasma ratio did not 
change. Th e sodium dialysate / plasma curves are similar for children and adults, suggesting 
a similar role for aquaporins both in children and adults. Th e theory that transport through 
the small pores is of great importance for the action of 7.5% icodextrin is supported by 
the fact that both in children and adults a relation was found between the mass transfer 
area coeﬃ  cient of creatinine and transcapillary ultraﬁ ltration, while this relation was not 
found using 3.86% glucose. 
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However our calculated data show a signiﬁ cant diﬀ erence in the water ﬂ ow through the 
aquaporins in both glucose and glucose polymer induced ultraﬁ ltration is present between 
children and adults. Th is diﬀ erence diminished as we calculated the absolute amount of 
the contribution of the aquaporin-mediated waterﬂ ow to the total ultraﬁ ltration coef-
ﬁ cient (see below).
Functional characterization of the peritoneal membrane
Th e UFC is the product of the peritoneal surface area (S) and its hydraulic permeability 
(Lp). In children 15% of the LpS is determined by aquaporins versus 5% in adults. Th is 
implies that the children in our study group have a 3 times higher amount of functional 
aquaporins as compared to the individuals in the adult study group. Lai et al (22) dem-
onstrated that transcription and biosynthesis of AQP-1 in human peritoneal mesothelial 
cells is signiﬁ cantly increased upon exposure to glucose in vitro. Th is upregulation of 
AQP-1 upon exposure to glucose is time- and dose-dependent. Th ey also demonstrated 
an absence of AQP-1 in peritoneal lining denuded of mesothelial cells and speculated 
that long-term PD might lead to decreased expression of AQP-1 on the peritoneal lining 
because of denudation of mesothelium. Th e negative correlation between the fractional 
trancellular UFC and treatment period in children indeed suggests a decreased expression 
of AQP in long-term PD. Th e absence of a relation between fractional transcellular UFC 
and age implies that the diﬀ erences observed in AQP function are not related to age groups, 
but are determined by other factors as duration of treatment and glucose exposure. It is 
also important to realize that the age range of the pediatric patients was small, as was the 
number of our observations. Th e current methodology makes it impossible to compare the 
(cumulative) glucose exposure between both study groups. A recent study has shown that 
aquaporins can be inactivated while they remain on the cell surface (23). Th is implies that 
inactivation of aquaporins can be accomplished through means other than degradation 
of the water channels. It is not yet clear what mechanism is responsible for the inhibition 
of the aquaporins but maybe this might be an explanation for the diﬀ erences found be-
tween children and adults. It also should be considered that the diﬀ erences in the amount 
of functional aquaporins are the result of a lower small pore area in the children. As the 
children are smaller they do have lower actual small pore areas. However by adjusting both 
the dwell volume and the transport parameters to the body surface area such diﬀ erences 
between adults and children are no longer expected. Th is is conﬁ rmed by the fact that 
the MTACs for small solutes are the same in children and adults, which means that the 
functional size of the small pore area will not be essentially diﬀ erent. 
Next to the observation of diﬀ erences in the amount of functional AQPs, the AQP-system 
seems also more eﬃ  cient in the pediatric study group, because 83% of glucose induced 
ultraﬁ ltration takes place through these aquaporins compared to 50% in adult patients. 
Th e eﬀ ectiveness of the system can be explained by the fact that LpS is a physical quantity 
that is deﬁ ned based on hydrostatical pressure (expressed as ml/min/mm Hg). Th e resist-
ance caused by the ultrasmall aquaporins is much larger than the resistance caused by the 
small pores. Th e reason why such a great part of the ultraﬁ ltration occurs through the 
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aquaporins is because PD is based on a crystalloid osmotic pressure instead of a hydrostatic 
pressure. 
 Further calculations show that the total amount of water, transported through the aquapor-
ins during a glucose dwell (UFCaqp) is the same for children and adults. Th is implicates 
– although it seems that there are diﬀ erences in the aquaporins between both study groups 
– that the eﬀ ect of the 3.86% glucose solution on the aquporins is exactly the same.
It can be concluded that ﬂ uid and solute parameters are similar for glucose polymer based 
dialysate and 3.86% glucose in children, except for the transcapillary ultraﬁ ltration. Th is 
can be explained by the absence of crystalloid osmosis and the fact that TCUF was meas-
ured after a 4-hour dwell.
Comparison of transport parameters and peritoneal membrane characteristics reveal that 
there seem to be diﬀ erences between the peritoneal transport pathways in children and 
adults, but these diﬀ erences do not interfere with the clinical eﬃ  cacy of the aquaporins 
since the absolute water ﬂ ow through the aquaporins is identical in both groups using 
3.86% glucose. Further studies are needed to explore the diﬀ erences between children and 
adults in the amount and the functionality of the aquaporins and the small pores. 
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Appendix A
The ultraﬁ ltration coefﬁ cient (UFC) can be calculated from the following equation:
TCUFR   = UFC [∆P - σΔΠ + σΔO] (Eq. 1)
in which TCUFR0-1 min is the maximal transcapillary ultraﬁ ltration rate obtained during 
the ﬁ rts minute of  an exchange, ΔP is the hydrostatic pressure gradient, ΔΠ is the colloid 
osmotic pressure gradient, and ΔO is the crystalloid osmotic pressure gradient. σ is the 
reﬂ ection coefﬁ cient that can range from 1.0 (ideal semipermeable membrane) to 0 (no 
osmotic effect). It was assumed that ΔP, during PET, has a constant value of  9 mm Hg, 
as the capillary pressure is about 17 mmHg (24) and the intraperitoneal pressure 8 mm 
Hg while resting (25). According to Van ‘t Hoffs law every mOsm/liter exerts an osmotic 
pressure of  19.3 mm Hg in the case of  an ideal semipermeable membrane. This implies 
that the osmotic pressure generated by an osmotic gradient is given by : [osmolality · σ · 
19.3]. The reﬂ ection coefﬁ cient of  albumin is generally considered to approach 1.0. The 
reﬂ ection coefﬁ cient of  icodextrin was calculated using the relation between reﬂ ection 
coefﬁ cients of  low molecular weight solutes (urea, urate, glucose, creatinine), and albumin, 
and their molecular weights. The molecular weight of  icodextrin (16,800 Da) resulted in 
a value of  0.767 for the reﬂ ection coefﬁ cient. The capillary colloid osmotic pressure (Πc) 
was assumed to be determined by the serum albumin concentration for 75% (26). To this 
value 0.04 was added because of  the Gibbs-Donnan equilibrium (26).
 Пc    = [ SA ·1000·4 + 0.4 ] ·19.3 (Eq. 2)  
           68,000   3
   = 0.38 SA + 7.72 mm Hg
In this equation SA represents serum albumin (g/liter), 68,000 is the molecular weight 
of  albumin, and the factor 1000 converts osmoles to mosmoles. The osmotic pressure 
within the peritoneal cavity (Πpc), exerted by icodextrin, equals:
 Пc  = [ DIC ·1000 ] · 0.767 · 19.3 (Eq. 3)  
            16,800 
     = 0.88DIC
in which DIC is the dialysate icodextrin concentration in g/liter, 16,800 is the molecular 
weight of  icodextrin, and 0.767 is the reﬂ ection coefﬁ cient.
Therefore the transcapillary ultraﬁ ltration rate through the small pores (TCUFRsp) during 
the initial phase of  the exchange, before absorption of  solutes has taken place, equals:
TCUFRsp  = UFCsp[ΔP – (Пc – Пpc)] (Eq. 4)
      = UFCsp[9 - 0.38SA - 7.72 + 0.88DIC]
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     = UFCsp[1.28 + 0.88DIC – 0.38SA]
The transcapillary ultraﬁ ltration during the ﬁ rst minute of  the dwell was considered to 
represent the initial transcapillary ultraﬁ ltration rate.
It implies that the UFC of  icodextrin (ID) can be written as:
UFCsp    =   
     TCUFR0-1min  (ID)          (ml/min/mm Hg) (Eq. 5)  
            0.88DIC - 0.38SA +1.28 
For 3.86% glucose a similar equation can be given:
TCUFR0-1min   = UFCtot[ΔP – Πc + σΔO] (Eq. 6)
ΔP was kept constant at 9 mm Hg and Πc was calculated according to [Eq. 2]. ΔO is the 
difference between the osmolality of  the dialysis ﬂ uid (486 mOsm/liter) and the plasma 
osmolality of  the patient (Osm). As σ glucose averages 0.03 (27), σΔO = 0.03 · (486 - 
Osm)· 19.3 mm Hg. Substitution of  these numbers in [Eq 6] yields: 
TCUFR0-1min   = UFCtot[9 – 0.38SA – 7.72 + 0.03(486 – Osm) · 19.3]
      (Eq.7)
Rearranging this equation yields:
UFCtot    =    
  TCUFR0-1min  (3.86%)    (ml/min/mm Hg) (Eq. 8)  
            283 - 0.38SA - 0.58Osm 
Subtraction of  equation (5) from equation (8) gives the UFC of  the aquaporins:
UFCaqp    =    
 TCUFR0-1min (3.86%)   –     TCUFR0-1min (ID)          
          283 - 0.38SA - 0.58Osm   0.88DIC - 0.38SA +1.28 
      (Eq. 9)
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Appendix B
The ultraﬁ ltration coefﬁ cient is the product of  the hydraulic permeability of  the peri-
toneum (Lp) and the surface area (S). It can be calculated from the initial transcapillary 
ultraﬁ ltration rate and the overall peritoneal pressure gradient according to Starling’s 
equation (see Appendix A):
 TCUFR0-1min = LpS[ΔP – σΔΠ + σΔO] (Eq. 10)
There are apparent differences for LpS values calculated using either icodextrin or glucose, 
while LpS is a membrane constant that is constant by deﬁ nition. The most probable expla-
nation is the heteroporosity of  the peritoneum. The presence of  aquaporins is especially 
important in this respect because they represent only a small proportion of  the surface 
area, but contribute largely to water ﬂ ow induced by crystalloid osmosis. Despite the small 
contribution by aquaporins to total peritoneal LpS, a very large proportion of  the osmotic 
force is exerted across this pathway. This is because the osmotic force is composed of  the 
fractional UFC values (across small pores and aquaporins), each multiplied by the solute 
reﬂ ection coefﬁ cient across each pore system.
For glucose the following calculation can be made, assuming a reﬂ ection coefﬁ cient of  
1.0 across the aquaporins and 0.03 across the small pores.
The partial osmotic forces are as follows:
Aquaporins:    X · LpS · 1.0 (Eq. 11)
Small pores : (1-X) · LpS · 0.03 = LpS[0.03 – 0.03X] (Eq. 12)
in which X is the the part of  LpS caused by aquaporins.
The fractional osmotic force across aquaporins now becomes:
          X              = UFCaqp (Eq. 13)  
  0.03 + 0.97X   
in which UFCaqp is the contribution of  aquaporins to UFCtot (see Appendix A, Eq. 9).
A similar calculation can be made for icodextrin, assuming a reﬂ ection coefﬁ cient of  1.0 
across aquaporins and 0.767 across the small pores. The partial osmotic forces are as 
follows:
aquaporins:  Y · LpS · 1.0  (Eq. 14)
small pores :   (1-Y) · LpS · 0.767= LpS[0.767 – 0.767Y] (Eq. 15)
in which Y is the fractional osmotic force across aquaporins as calculated according to 
equation 13.
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The fractional osmotic force across aquaporins now becomes:
               Y               = UFCaqp (Eq. 13)  
    0.767 + 0.233Y   
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Abstract
Objective: To establish the intraperitoneal pressure (IPP) in a relatively large pediatric study 
group. To study the eﬀ ect of a 3.86% glucose solution and a 7.5% icodextrin solution on 
IPP during a 4-hour dwell.
Design: IPP measurements with the patient in a supine position. Th e intraperitoneal volume 
(IPV) was 1200 ml/m² of a 1.36% glucose solution. Th e inﬂ uence of dialysis solutions 
was obtained performing two 4-hour peritoneal equilibration tests (PETs) with 3.86% 
glucose and 7.5% icodextrin as a test solution respectively, using an IPV of 1200 ml/m2 
and Dextran 70 as a volume marker. Th e IPP was measured at 2 consecutive time points 
(t = 0 and 240 min). Transcapillary ultraﬁ ltration (TCUF), net ultraﬁ ltration (UF) and 
marker clearance (MC) were calculated.
Patients: IPP was established in 30 patients with a median age of 4.5 years (range 1.0-14.9). 
Inﬂ uence of dialysis solutions on IPP was studied in 9 children with a median age of 4.2 
years (range 1.7-10.9) and a median treatment period of 12 months (range 5.6-122.3). 
Results: Mean IPP was 12.3 cmH2O ± 6.4. A signiﬁ cant relation was found between the 
change in IPP and the TCUF and BSA during a PET with 3.86% glucose. No relations 
were seen during the PET with icodextrin.
Conclusions: IPP as established in a large pediatric study group is similar to previously 
published values of IPP in a small number of patients. Diﬀ erences in ﬂ uid kinetics have 
diﬀ erent eﬀ ects on the change in IPP during a 4-hour dwell period.
Keywords:
Peritoneal dialysis, children, intraperitonea pressure, icodextrin,3.86% glucoe soltiIntro-
duction
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Introduction
Th e hydrostatic intraperitoneal pressure (IPP), measured in the supine position in patients 
on automated PD, has proven to be a valuable, objective tool to analyze the individual 
tolerance for intraperitoneal volume (1-5). Determination of an optimal intraperitoneal 
volume (IPV) enables optimization of solute clearance in combination with a dwell volume, 
which is well tolerated by the patient (3,5,6). As a consequence IPP is one of the parameters 
that should be measured if one wants to create an optimal individualized prescription of a 
dialysis regimen is desired. Besides the inﬂ uence of the IPV on the IPP other parameters, 
such as age (7,8), body size (8,9) body mass index (8), time-induced adaptation (1) and 
degree of biocompatibility of the dialysis ﬂ uid used (10) also have impact on the IPP. Un-
til now studies concerning the IPP in pediatric peritoneal dialysis (PD) were performed 
in small groups of only 6 to 8 children (2,3,6,7). Data on IPP in a larger study group 
are desirable. Th e inﬂ uence of dialysis ﬂ uids containing diﬀ erent osmotic agents on the 
intraperitoneal pressure was also studied by comparing the intraperitoneal pressure and 
transport parameters using an icodextrin- and a 3.86% glucose-solution under similar test 
conditions in pediatric patients on chronic PD. 
Methods
IPP measurement
Th e IPP was measured in a group of 30 children (19 boys, 11 girls) with a median age of 
4.5 years (range 1.0-14.9) and a median duration of PD-treatment of 13 months (range 
3.2-140.7). All children were in nightly intermittent peritoneal dialysis (NIPD). IPP 
measurements were performed at the occasion of a peritoneal equilibration test (PET), 
which is routinely performed every six months in children on chronic peritoneal dialysis. 
In each child one test was performed. Prior to instillation of the test solution for the PET, 
the peritoneal cavity was rinsed with 1200 ml/ m² body surface area (BSA) of a 1.36% 
glucose solution (Dianeal®, Baxter B.V. Utrecht, Th e Netherlands). Th e IPP was measured 
after completion of the inﬂ ow and just before drainage of the 1.36% glucose solution. 
Th e IPP was measured as described by Fischbach et al (4,5). Th e IPP was measured with 
the patient in a complete supine position. IPP was expressed in centimeters of water by 
measuring the height of the column of dialysate in the line of a disconnect system. Th e 
reference point was set at the center of the abdominal cavity, on the midaxillary line. Because 
we used single bag systems a trocar was introduced at the injection site of the bag, before 
the readings were made, to avoid counterpressure in the distal part of the measurement 
tubing. Th e level of the column of dialysis ﬂ uid was read after deep inspiration (IPPin) 
and after deep expiration (IPPex). Adding the IPPin and IPPex and dividing the addition 
sum by 2 determined the mean IPP.
Inﬂ uence of different dialysis ﬂ uids on IPP
In a group of nine children (median age 5.5 years; range 1.8 – 12.5) we studied the inﬂ uence 
of a 3.86% glucose solution and a 7.5% icodextrin solution on IPP and the change in IPP 
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in relation to ﬂ uid kinetics. In each child two PETs were performed as described previ-
ously (11); one PET was performed with a 3.86% glucose solution (Dianeal®, Baxter B.V. 
Utrecht, Th e Netherlands) and the other was performed with a 7.5% icodextrin solution 
(Extraneal®, Baxter B.V. Utrecht, Th e Netherlands). Th e 4-hour dwell was performed with 
an IPV of 1200 ml/ m² BSA and dextran 70 (Macrodex NPBI, Emmercompascuum, Th e 
Netherlands) was added to the test solution as a volume marker to calculate ﬂ uid kinetics. 
A serum sample was taken at the start of the study. Dialysis ﬂ uid was sampled at the start of 
the study and at 5, 30, 60, 120, 180 and 240 minutes after instillation of the test solution. 
Th e 2 PET’s were performed with a median interval of 5.6 months (range 4.9-6.2 months) 
and all PET’s were performed at least two months after any peritonitis episode. Th e IPP 
(cmH2O) was measured at 2 distinct time points. Th e ﬁ rst IPP measurement (IPP1) was 
performed during the rinsing procedure before the 4-hour dwell, as described in the sec-
tion IPP measurement. Th e second IPP measurement (IPP2) was performed directly after 
dialysate sampling at t= 240, just before drainage of the test solution.
Th e transcapillary ultraﬁ ltration (TCUF), the marker clearance (MC) and the net ultraﬁ l-
tration (netUF) were calculated according to previously described formulas (11). In brief 
TCUF was calculated from the dilution of the volume marker, by subtracting the initial 
theoretical IPV from the theoretical IPV. Th e theoretical IPV is the IPV in the absence 
of marker clearance and sampling, in which marker clearance equals the disappearance of 
ﬂ uid from the peritoneal cavity. MC was deﬁ ned as the diﬀ erence between the amount 
of dextran 70 instilled and the total amount recovered, divided by the product of dwell 
time and the mean dextran 70 concentration. ∆-IPP was calculated using the equation: 
∆-IPP = IPP2 – IPP1. 
Results are expressed as mean and standard deviation (SD) or median and ranges. For com-
parison of the results of the two solutions in 9 children a Students t-test for paired samples 
was performed. Correlations were tested using the Spearman rank correlation analysis. 
Mean ± SD p-valuea
IPP 12.0 ± 6.5
Age 6.0 ± 3.9 NS
Duration PD 27.9 ± 37.2 NS
BSA 0.76 ± 0.25 NS
BMI 16.5 ± 1.4 NS
Table 1. IPP measurement in a group of 30 children 
Results of IPP measurements and characteristics of the study group. In each patient one test 
was performed.
a = Spearman rank correlation analysis : relation between IPP and age, duration PD, BSA 
and BMI. Th ere are no signiﬁ cant relations found between IPP and the other parameters
IPP = intraperitoneal pressure (cmH2O), age (years), duration PD (months), BSA = body 
surface area (m2), BMI = body mass index (kg/m²)
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Results
IPP measurement
Patient characteristics and results of the IPP measurements are given in table 1. Th e mean 
IPP was 12 ± 6.5 cmH2O in a group of 30 children. Th ere were no relations found between 
the IPP and age, duration of PD, BSA and BMI. Th ere was no signiﬁ cant diﬀ erence in 
IPP measured in boys and girls.
Th e median inﬂ ow volume used was 1188 ± 57 mL/m² BSA, while the median ﬁ ll volume 
for the chronic routine prescription was 902 ± 134 mL/m² BSA.
Inﬂ uence of different dialysis ﬂ uids on IPP
Results of the measurement of IPP and ﬂ uid parameters obtained during a PET with 3.86% 
glucose and icodextrin in the 9 children who underwent both PETs are given in table 2. 
IPP1 was not signiﬁ cantly diﬀ erent between the PET performed with glucose 3.86% and 
the one performed with icodextrin. IPP2 was also not signiﬁ cantly diﬀ erent between the 
2 solutions. Th e ﬂ uid parameters TCUF, MC and netUF were signiﬁ cantly higher for the 
3.86% glucose group. In the 3.86% glucose PET IPP1 had a negative correlation with 
Parameter Group Mean SD P-value
IPP1 3.86% glucose 11.4 7.0 NS
Icodextrin 10.6 3.7
IPP2 3.86% glucose 16.1 6.1 NS
Icodextrin 12.4 4.5
TCUF 3.86% glucose 1053 150 <0.001
Icodextrin 278 153
MC 3.86% glucose 348 241 0.04
Icodextrin 150 140
NetUF 3.86% glucose 857 125 <0.001
Icodextrin 156 147
Time on PD 3.86% glucose 27.6 35.9 NS
Icodextrin 35.4 40.9
Age 3.86% glucose 5.7 3.4 NS
Icodextrin 6.2 3.3
Table 2. Student-t test for paired samples. Comparison of transport parameters obtained 
during a 3.86% glucose peritoneal equilibration test (PET) and an icodextrin PET in 9 
children on chronic PD. IPP (cmH2O) = intraperitoneal pressure, TCUF (ml/1.73 m
2) = 
transcapillary ultraﬁ ltration, MC (ml/1.73 m2) = marker clearance, netUF (ml/1.73 m2) = 
net ultraﬁ ltration , time on PD (months).
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1A
1B
Figure 1. Spearman rank correlations between ∆-IPP and transcapillary ultraﬁ ltration 
(TCUF) and body surface area (BSA) using two diﬀ erent test solutions (3.86% glucose and 
7.5% icodextrin) during a Peritoneal Equilibration Test (PET) in 9 children. (A) Relation 
between ∆-IPP and TCUF during a 3.86% glucose PET (B) Relation between ∆-IPP and 
BSA during a 3.86% glucose PET,
Delta-IPP (cmH2O) = ∆-IPP = IPP2-IPP1, TCUF (ml/1.73 m
2), BSA (m2)
MC (r = -0.91,P < 0.01). No relation was found with TCUF, UF and age. No signiﬁ cant 
change of ∆-IPP was found in relation to duration of PD, UF and MC. A signiﬁ cant 
change of ∆-IPP was found in relation to TCUF (r= 0,67, P = 0.05) and BSA (r = -0.81, 
P = 0.01) (ﬁ gure 1a, 1b). No correlation was found between BSA and UF.
r = -0.81, P=0.01
-4
-2
0
2
4
6
8
10
12
14
16
0 0,2 0,4 0,6 0,8 1 1,2
BSA
D
el
ta
 IP
P
-4
-2
0
2
4
6
8
10
12
14
16
0 200 400 600 800 1000 1200 1400
TCUF
de
lta
 IP
P
82
C
ha
pt
er
 2
1C
1D
Figure 1. 
(C) Relation between ∆-IPP and TCUF during an icodextrin PET
(D) Relation between ∆-IPP and BSA during an icodextrin PET. 
In the icodextrin group no relation was found between IPP1 and MC (r = -0.18, P = 0.64), 
TCUF, UF and age. No correlations were present between ∆-IPP and duration of PD, 
TCUF (ﬁ gure 1c), UF, MC or BSA (ﬁ gure 1d). 
None of the patients experienced any allergic reaction or peritoneal pain due to the ad-
dition of dextran 70.
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Discussion
In a number of studies Fischbach et al. have studied the IPP in children on chronic PD 
(1-4, 6,7). Th ey studied the inﬂ uence of several parameters on IPP (age, posture, IPV, body 
size and BMI) and indicated that IPP overall appears to be an individual parameter. Th ey 
also brought attention to the usefulness of IPP as a tool to optimize individual dialysis 
prescriptions in children. 
Measurement of the total pore area over diﬀ usion distance (A0/∆X) of the peritoneal 
membrane -also called the peritoneal exchange area- has proven to be a reliable indicator of 
peritoneal membrane function (12). Th e A0/∆X is related to the area of the peritoneum that 
is in contact with dialysis ﬂ uid and consequently the intraperitoneal ﬁ ll volume dynamically 
aﬀ ects A0/∆X (13,14). As IPP measurement can be used as an objective assessment of ﬁ ll 
volume tolerance (7), IPP measurement in combination with determination of A0/∆X will 
allow to create an optimal individualized prescription of a dialysis regimen. 
Th e aim of this study was to establish the IPP in children in a larger patient group and 
examine the inﬂ uence of dialysis ﬂ uids containing diﬀ erent osmotic agents on IPP. Th e IPP 
was measured in a supine position with 1200 ml/m² BSA of a 1.36% glucose solution in 30 
children on chronic peritoneal dialysis. Th e values of IPP were in the same range as those 
reported in literature, obtained in the same age group, with similar ﬁ ll volumes and with 
the same body position (7). It should be realized that bicarbonate buﬀ ered dialysis ﬂ uids, 
having a more biocompatible pH and containing less glucose degradation products will 
give rise lower IPP’s (10). Th is positive eﬀ ect of the newer dialysis ﬂ uids probably is thanks 
to the occurrence of less inﬂ ow pain (10). In our study none of the children complained of 
inﬂ ow pain. However we did not measure pain perception by use of a visual pain scale. It 
also should be realized that an increase of IPV induces an increase in the peritoneal surface 
area in contact with the dialysis ﬂ uid. Chagnac et al. observed a signiﬁ cant increase of this 
“wetted” area after a 50% increase of the IPV (14). In our study we used an IPV, which 
was approximately 28% higher than the chronic routine prescription. We were not able 
to demonstrate a diﬀ erence in IPP between genders as was seen in a group of 81 adult 
patients (9), and in a group of 17 pediatric patients (8). In both study groups the IPP 
was approximately 2 cmH2O higher in males compared to females, and it was concluded 
that physical characteristics as gender and muscle tone are determinants of IPP (9). Based 
on our results it can be concluded that gender plays no major role in determining IPP 
in pediatric patients. Another relation that was not found in our study was the relation 
between BMI and IPP. Th e results of previous studies performed in children (8) and adults 
(9) showed an interesting relation between body size and IPP, which implied the need to 
look at body size for optimization of ﬁ ll volume prescription. Th e variation in BMI in our 
study was, however, small. 
Th e second part of our study describes the eﬀ ect of diﬀ erent osmotic agents on IPP during a 
4-hour dwell. IPPs were measured at 2 consecutive time points during a PET performed with 
icodextrin and a PET performed with 3.86% glucose as a test solution. In both PETs IPP1 was 
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measured at the end of a rinsing procedure with 1.36% glucose (1200 ml/m² BSA). Because 
1.36% glucose exerts only a small osmotic eﬀ ect it can be concluded that IPP1 is not inﬂ u-
enced by an unintended increase in volume. Measuring IPP1 under the same circumstances 
also allowed us to detect changes in patient conditions, which possibly could have occurred 
in the time that elapsed between the two PETs. Since IPP1 was not signiﬁ cantly diﬀ erent 
in a paired samples test, we assumed that no important changes in patient conditions had 
occurred. Th e IPP plays an important role in the ﬂ uid movement from the peritoneal cavity 
into the body. Previous studies have shown that this ﬂ uid movement is mainly dependent on 
intraperitoneal hydrostatic pressure and relatively independent on osmotic pressure (15,16). 
Durand et al. observed in adult patients that ultraﬁ ltration was inﬂ uenced to a great extent 
by the intraperitoneal pressure (17). Th is is illustrated by our data showing a strong negative 
correlation between IPP1 and the MC during the 3.86% glucose PETs while during the 
icodextrin PETs there was no relation found between IPP1 and MC. Th is can be explained by 
diﬀ erence in ﬂ uid kinetics between 3.86% glucose and icodextrin. Using a 7.5% icodextrin 
solution there was a signiﬁ cantly lower netUF after the 4-hour dwell period compared to 
netUF obtained with 3.86% glucose. Th is has also been reported in adult patients (18). As 
a consequence the hydrostatic pressure will not rise suﬃ  ciently to inﬂ uence ﬂ uid movement 
from the peritoneal cavity into the body using icodextrin during a 4-hour dwell period. As 
icodextrin exerts its osmotic eﬀ ect for up to 12 hours, it will be interesting to evaluate IPP 
after a 12-hour dwell with icodextrin. Th e correlation present between ∆-IPP and BSA dur-
ing the glucose 3.86% PETs implies that there is a higher increase in IPP during a 4-hour 
dwell with glucose 3.86% in patients with a smaller body size. Th ese data conﬁ rm results 
obtained in a study in 14 pediatric patients that showed an initial increase in IPP secondary 
to an increase in IPV (IPV). Th e increase in IPP was more prominent in younger children 
(7). Th e absence of this correlation during the icodextrin PETs is explained by the smaller 
increase in IPV. It is not very likely that the diﬀ erences are due to the tendency of higher IPPs 
with acidic dialysis ﬂ uids as compared to IPPs measured with more neutral dialysis ﬂ uids 
(10) since both dialysis ﬂ uids we used in this study have an acidic pH (icodextrin:5.2 and 
glucose 3.86%: 5.5). A study in adult patients showed that there is no relationship between 
IPP and the subjective discomfort degree experienced by patients, although the mean dis-
comfort experienced was higher with larger dialysate volumes (9). As a consequence it seems 
important to observe the individual degree of comfort using a larger dialysate volume of a 
solution with a high glucose concentration, especially in small children. 
It is concluded that IPP measured in a relatively large pediatric group of 30 patients are 
similar to those reported in these studies performed in smaller patient groups with the 
same ﬁ ll volume. Due to the diﬀ erence in ﬂ uid kinetics between icodextrin and 3.86% 
glucose the two solutions have a diﬀ erent eﬀ ect on the change of IPP during a 4-hour 
dwell period. When using an osmotic agent that induces a rapid ultraﬁ ltration the increase 
in IPP is inversely related with BSA. When using an osmotic agent that induces a slow 
but sustained ultraﬁ ltration IPP hardly increases after a 4-hour dwell and no relations are 
found with ﬂ uid kinetics or patient characteristics. Further studies are needed to evaluate 
such relations after a longer dwell.
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Introduction
Renal anemia in pediatric patients treated with chronic peritoneal dialysis can be eﬀ ectively 
treated with erythropoietin (EPO) (1-3). Until now, subcutaneous injection has been the 
most often used mode of administration (3,4). Intraperitoneal administration has proven 
to be an alternative method of treatment (1,2,5). Th is application route is preferred be-
cause subcutaneous injections may be painful and frightening for the child. Th e major 
disadvantage seems to be the need for higher maintenance doses (1,4). In the present study 
we describe the results of a long-term therapeutic study in which EPO was administered 
in 50 mL of dialysis ﬂ uid.
Patients and methods
Th e study population consisted of 20 children (8 girls and 12 boys) with a median age 
of 3.8 years (range 0.9-14). All were treated with nightly intermittent peritoneal dialysis 
(NIPD) during the study period and had been treated for a median period of 5 months 
(range 0-108 months).
Patients started with a weekly dose of 200 units of EPO (Eprex, Janssen-Cilag) per kilo-
gram bodyweight. Th e EPO was administered three times per week in dialysis bags that 
were made especially for this purpose (Baxter BV, Utrecht, Th e Netherlands). Th ese bags 
contained 50 mL of NaCl 0.9% solution. Th e parents injected the hormone into the bags 
themselves. Th e bags were instilled after complete drainage of the abdomen for a 10- to 
12-hour dwell during the day.
Th e target hemoglobin level was 104-112 g/L. Dosage was adjusted every two months; 
EPO dosage was increased by 75 U/kg/week until the target level was reached. Dosage 
was decreased by 75 U/kg/week if the Hb concentration exceeded 112 g/L. Hemoglobin, 
hematocrit and the number of reticulocytes were assessed every 4 weeks. Serum ferritin 
levels and transferrin saturation were assessed every two months, and iron supplementation 
was prescribed in the case of iron deﬁ ciency (serum ferritin below 100 mg/L; transferrin 
saturation below 20%).
Results
Patients were treated with EPO administered in 50 mL of dialysis ﬂ uid for a median period 
of 10 months (range 3-12 months). 
Th e median Hb level was 94.4 g/L at the start of the study and increased to 105.6 g/L 
(range 80-134.4) and 110.4 g/L (range 89.6-131.2) after 3 and 12 months of treatment, 
respectively (Figure 1).
Th e median EPO dosage was 200 U/kg/week at the start of the study and remained stable 
during the study period (Figure 2). During the last 2 months of the study period, the range 
of EPO dosage was very broad. Th is was due to a very high dosage of 715 U/kg/week in 
1 child. Th is high dosage was given after a rapid decline in the hemoglobin concentration 
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from 108.8 g/L to 92.8 g/L, during a period of peritonitis. 
Eighteen of 20 children received oral iron supplementation (2-3 mg/kg/day) because of 
iron deﬁ ciency. 
Figure 1 Minimum, median and maximum hemoglobin level (g/L) during intraperitoneal 
administration of erythropoietin in 50 ml of dialysis ﬂ uid. N: number of patients.
Figure 2 Minimum, median and maximum erythropoietin dosage with intraperitoneal 
administration of erythropoietin in 50 ml of dialysis ﬂ uid. N: number of patients.
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Th e peritonitis incidence during the study period was 1 episode every 11.2 patient 
months.
Discussion
Th e main disadvantage of intraperitoneal administration of EPO seems to be the need for 
higher maintenance doses. However, it was established that the absorption of EPO after 
intraperitoneal administration is similar to absorption after subcutaneous administration 
if the EPO is added to a small volume (50 mL) of dialysis ﬂ uid (2,5,6). 
Th e present study describes the results of a long-term therapeutic study in a study popula-
tion of 20 children. Th e median EPO dosage remained stable throughout the study period 
and was 179 U/kg/week after 12 months. 
Th e results of this study demonstrate that the intraperitoneal administration of EPO in 50 
mL saline leads to an eﬀ ective treatment of renal anemia. Maintenance doses are similar 
to those when using the subcutaneous administration route (3). Th ere have been recent 
studies in which awareness of the possibility of suﬃ  cient absorption of EPO was expressed 
(4,7) and positive ﬁ ndings have also recently been reported(8,9). 
A former study of our group showed no relationship between intraperitoneal EPO and 
an increased risk of peritonitis (1). During the study period, no problems occurred with 
intraperitoneal administration. Th e parents did not experience an increase in the burden 
placed on them. In all our patients, dialysis adequacy (Kt/V³ 2.2) was obtained without 
the need for daytime dwells, thus allowing daytime EPO therapy.
We think that intraperitoneal EPO should replace the subcutaneous administration of this 
hormone in pediatric patients.
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Abstract
Objective: To evaluate the use of the combination of cefazolin and ceftazidime for initial 
treatment of PD related peritonitis in pediatric patients.
Design: Retrospective nonrandomized study.
Setting: Pediatric dialysis units of the University Medical Center of Utrecht and Nijmegen, 
Th e Netherlands. 
Patients: 40 children (median age 5.4 years) who were treated with PD during the study 
period of 4.5 years. 
Interventions: All 50 episodes of peritonitis that occurred during the study period were 
evaluated by review of medical records. Patients were given intraperitoneal ceftazidime 500 
mg/L dialysis ﬂ uid, and cefazolin 500 mg/L as a loading dose, followed by a maintenance 
dose of ceftazidime 125 mg/L and cefazolin 100 mg/L, intraperitoneally, 4 times daily. 
Antibiotics were continued for 14 days. 
Results: After identiﬁ cation of the causative microorganism, one of the antibiotics was 
discontinued in 34 cases, and the antibiotic schedule was adapted in 2 cases. All cases 
were initially cured within 3 days. In 5 cases (10%) there was a peritonitis with the same 
organism recurring within 2 weeks after completion of treatment. Th ere were 4 cases of 
PD-related peritonitis caused by pseudomonas, all of which were cured.
Conclusions: Th e antibiotic combination of cefazolin and ceftazidime is eﬀ ective for the 
initial therapy of PD-related peritonitis in children. Th e toxic complications of aminogly-
cosides are avoided with this combination.
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Introduction
Th e most recent international treatment guidelines regarding peritoneal dialysis (PD)-as-
sociated peritonitis in children propose the use of continuous therapy with a combination 
of intraperitoneal (IP) cephalosporin and aminoglycoside (1).
Th e use of aminoglycosides has to be questioned, because of its toxicity proﬁ le (2,3). When 
2 of our patients suﬀ ered hearing loss following tobramycin given in the recommended 
dose, we decided to replace tobramycin by ceftazidime, a third-generation cephalosporin. 
Th e present study evaluates our experience with this combination of a ﬁ rst- and a third- 
generation cephalosporin in the treatment of peritonitis in pediatric patients on PD.
Patients and methods
We reviewed all cases of peritonitis in children on PD during the 4.5-year period spanning 
1 September 1994 to 1 April 1999. Th e medical records of 40 children (24 boys, 16 girls; 
median age 5.4 years, range 3 months to 18.9 years) were studied. Th e patients had been 
treated for a total of 665 patient-months, with an average of 15 dialysis treatment months 
(range 1-40 months) per patient. Th irty-three children were treated with automated PD 
(nocturnal intermittent PD) , 6 with continuous ambukatory peritoneal dialysis (CAPD), 
and 2 children switched from CAPD to automated PD during the study period.
Peritonitis was deﬁ ned as cloudy peritoneal eﬄ  uent associated with an increased number of 
white blood cells (>100/mm3) and/or micro-organisms in the dialysate eﬄ  uent demonstrated 
by culture and/or associated with abdominal pain (4). Cases that did not match the deﬁ nition, 
cases with asymptomatic cloudy peritoneal eﬄ  uent showing more than 15% eosinophils on 
a diﬀ erential cell count (eosinophilic peritonitis) (4), and cases that were not initially treated 
with a ﬁ rst- and a third-generation cephalosporin were excluded from analysis.
Resolution of peritonitis was deﬁ ned as disappearance or improvement of peritoneal 
dialysate cloudiness and clinical symptoms within 3 days after the initiation of antibiotic 
therapy. Recurrence was deﬁ ned as a peritonitis with the same organism recurring less than 
2 weeks after treatment completion.
When peritonitis was diagnosed, patients were switched to standard CAPD. Antibiotic 
therapy was started with IP ceftazidime 500 mg/L and cefazolin 500 mg/L as a loading 
dose, followed by a maintenance dose of 125 mg/L ceftazidime and 100 mg/L cefazolin 
IP, 4 times daily, for a 14-day period. As soon as culture results were available, therapy 
was evaluated. Depending on the sensitivity of the causative microorganism, therapy was 
adjusted and one of the antibiotics was discontinued.
Culture techniques were slightly diﬀ erent in the two university hospitals where the study 
was performed. For culture of dialysis ﬂ uid, 10 mL of dialysis ﬂ uid was centrifuged and 
smeared on a blood agar plate and a MacConkey agar plate in one hospital; in the other 
hospital, 3 times 15 mL dialysis ﬂ uid was centrifuged and put, respectively, on 1 blood 
agar plate, 1 chocolate agar plate and 1 serum broth and cysteine agar plate.
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Results
During the study period, 27 of our patients had 50 episodes of peritonitis that were initially 
treated with a ﬁ rst- and a third-generation cephalosporin. Th irteen patients remained free 
of peritonitis during the study period. Th e incidence of peritonitis was 1 episode every 
11.9 patient months.
A variety of organisms caused the peritonitis; Table 1 lists the causative organisms. Perito-
neal ﬂ uid cultures were negative in 13 episodes (26%); the ﬁ rst method described above 
had a rate of 26.9% of sterile cultures, and the second method had a rate of 23.3 %. Th is 
diﬀ erence was not signiﬁ cant (c²=3.18, p= 0.07). Th ere was one case in which no culture 
was done. 
After identiﬁ cation of the causative micro-organism, one of the antibiotics was discontin-
ued in 34 cases. In all but one case, the causative micro-organism was susceptible to either 
ceftazidime or cefazolin. In all 16 cases caused by staphylococci, there was no methicillin 
resistance. Th e antibiotic schedule was adjusted in two cases. Ceftazidime was replaced by 
cotrimoxazole in a case caused by Klebsiella oxytoca and Stenotrophomonas maltophilia, 
because of resistance of Stenotrophomonas maltophilia to ceftazidime and cefazolin. 
Based on signs of sepsis at clinical presentation, intravenous instead of IP administration 
of ceftazidime was used during the ﬁ rst 2 days of treatment in a case of peritonitis caused 
by pseudomonas. In all 50 peritonitis episodes, cloudiness of peritoneal ﬂ uid and clinical 
symptoms improved within 3 days after the initiation of antibiotic therapy. Th ere were 5 
recurrences of peritonitis with the same organism less than 2 weeks after the completion 
of treatment of peritonitis (1 Staphylococcus aureus, 2 S. epidermidis, 1 enterobacter, 
1 corynebacterium). Th ese relapses were treated in exactly the same way as the primary 
Causative organism Episodes (n)
Staphylococcus aureus 9
S. epidermidis 7
Pseudomonas sp 4
Streptococcus sp 6  (Strept. Viridans 3; Hemolytic group A 2; Strept. Sanguis 1)
E.coli 2
Enterococcus 1
Enterobacter 1
Haem. Inﬂ uenzae 1
Corynebacterium 1
Acinetobacter 3
Klebsiella oxitoca + Stenotrophomonas 
maltophilia 1
Table 1. Organisms isolated from the dialysate of 27 children during 50 peritonitis episodes
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episodes and all were cured. Th ere were no new relapses. Th is means that the combination 
of ceftazidime and cefazolin was eﬀ ective in 90% of the episodes. 
Discussion
Th e international treatment guidelines regarding peritoneal dialysis-associated peritonitis 
in children propose the use of a combination of IP cephalosporin and aminoglycoside (1). 
Th e use of aminoglycosides has to be questioned because of their toxicity proﬁ le (2,3). 
Aminoglycosides have cochlear and vestibular ototoxic eﬀ ects, which are in part responsible 
for sensorineural hearing loss in pediatric patients with chronic renal failure (2). Th ey also 
seem to increase the rapidity of decline in residual renal function in peritoneal dialysis pa-
tients; residual renal function is an important independent predictor of technique survival 
in peritoneal dialysis therapy (3).
We evaluated our experiences with the combination of cefazolin and ceftazidime as initial 
treatment of peritoneal dialysis-associated peritonitis in 27 children (50 episodes). Th e use 
of this combination is in line with the current recommendation for initial treatment of 
peritonitis of the International Society for Peritoneal Dialysis (ISPD) year 2000 guidelines 
for adult patients (5). 
Ceftazidime is a third-generation cephalosporin with an antibacterial proﬁ le against gram-
negative organisms that is similar to the antibacterial proﬁ le of aminoglycosides, but with 
less-serious side eﬀ ects. Compared to the other third-generation cephalosporins, ceftazidime 
has similar activity against Enterobacteriacae and better activity against pseudomonas. 
Th e incidence of peritonitis in our study population falls within the range of other pedi-
atric studies (6,7). Initial treatment with a combination of ceftazidime and cefazolin has 
an acceptable success rate. Schaefer et al. recently published a success rate of 86.1% with a 
combination of glycopeptide and ceftazidime (7). Even though we have to take into account 
that his deﬁ nition of relapse was diﬀ erent from ours (recurrence within 4 weeks instead 
of 2 after completion of treatment), our results are comparable. Th e use of glycopeptides 
has to be questioned because of its ototoxic and nephrotoxic eﬀ ects. Initial therapy with 
cefazolin and levoﬂ oxacin gave improvement of symptoms at 48 hours in 94% of all epi-
sodes of peritonitis in adult patients on peritoneal dialysis (8).
Adult patients presenting streptococcal peritonitis seem to have a considerably higher 
peritonitis rate than other patients (9). In our pediatric patients, this was not the case. 
Our cases also did not follow a severe course, in contrast with some cases reported in the 
literature (10,11). Th e incidence of streptococcal peritonitis in our population is high (13 
%) compared with other studies (3-6%) (7,11,12).
Th e incidence of sterile cultures was high in our analysis, even though this incidence is 
similar to results described in the literature (7,13). A possible explanation may be the use 
of relatively small volumes of dialysate for culture. Th e recently published guidelines for 
adults recommend the use of larger volumes (≥ 50 mL) to maximize bacterial recovery 
rates (5).
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One of the advantages of using ceftazidime is its good activity against pseudomonas. In 
our population, we had a succes rate of 100% in pseudomonas peritonitis (4 cases) using 
ceftazidime monotherapy. Good results are reported with the combination of ceftazidime 
and ciproﬂ oxacin in the treatment of pseudomonas peritonitis in adult patients on peri-
toneal dialysis (14,15). Even though our study group is small, we think initial treatment 
with ceftazidime is a good possibility for treatment of Pseudomonas peritonitis.
A possible disadvantage of the combination of cefazolin and ceftazidime is the resistance 
of methicillin-resistant Staphylococci to this combination. If these micro-organisms are 
diagnosed or suspected, the antibiotic treatment regimen has to be adjusted.
Th e present study describes the continuous treatment with the combination of a ﬁ rs-t 
and a third-generation cephalosporin. Based on recent publications showing good eﬀ ects 
with the intermittent administration of these antibiotics, the combination described in 
this study might also be suitable for discontinued therapy. Th is will be advantageous to 
the majority of pediatric patients that are on a nocturnal intermittent PD dialysis regimen 
and do not have to switch to CAPD. Th e combination of glycopeptides and ceftazidime 
showed good eﬀ ects with intermittent administration (7) and another study showed ef-
fective serum concentrations (greater than the minimum inhibitory concentration over 
48 hours) with intermittent dosing of cefazolin (16). 
We conclude that initial treatment with IP cefazolin and ceftazidime is eﬀ ective in peritoneal 
dialysis-associated peritonitis in children. Side eﬀ ects of aminoglycosides are avoided with 
this combination. Also, the use of vancomycin as an initial therapy is avoided.
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Introduction
Continuous ambulatory peritoneal dialysis (CAPD) and nightly intermittent peritoneal 
dialysis (NIPD) in young children with end-stage renal failure are often associated with 
feeding disturbances such as anorexia, nausea and vomiting. Th ese feeding disturbances 
are likely caused by chronic renal failure and its treatment.
Because little is known about the mechanism underlying feeding disturbances in young 
children treated with peritoneal dialysis we examined the existence of a pathological 
gastroesophageal reﬂ ux (GER) and quantiﬁ ed intestinal passage by measuring the mouth-
to-caecum transit time (MCTT) in young children treated with peritoneal dialysis.
Patients and methods
After obtaining written informed consent from each patient’s relatives, the MCTT and 
the presence of pathological GER were evaluated in children treated with peritoneal 
dialysis. All children had end-stage renal disease and were without prokinetics or other 
drugs with known inﬂ uence on gastrointestinal function. Th is study was approved by 
the local ethics committee.
In 8 children treated with CAPD (four daily exchanges of 40 mL/kg; mean age 5.0 years, 
range 0.2-9.6 years) the MCTT was investigated by a lactulose hydrogen breath test, using 
a Lactoscreen (Hoekloos, Schiedam, Th e Netherlands) as described by Van der Klei et 
al. (1). None of the patients had feeding disturbances. Basal H2 expiration was assessed 
after a 9-hour fast during which patients received their normal dialysis prescription. Th e 
MCTT was recorded according to standardized methods; the normal values for MCTT 
were taken from the study by Vreugdenhil et al. (2).
Th e presence or absence of pathological GER was also assessed in 8 children ( mean age 
5.6 years, range 0.8-14.7 years) by 24-hour pH monitoring. Feeding disturbances were 
present in 6 patients. Five patients were being treated with CAPD (four daily exchanges 
of 40 mL/kg) and 3 patients were being treated with NIPD (nightly exchanges of 40 
mL/kg). Th e pH probe was a ﬂ exible glass electrode (type Lot 440-M4, Ingold/Mettler, 
Solthurn, Switzerland). Th e probe was introduced transnasally and located at the third 
vertebra above the diaphragm, according to Vandenplas (3). Localization was controlled 
by radiography . 
In this study we considered the reﬂ ux index (RI). Reference data were obtained from 
Vandenplas et al. (3,4). Th ey found the RI, (the sum of the periods with a pH < 4 , ex-
pressed in percentage of time of the total investigation time) a highly reliable parameter 
for documenting reﬂ ux in children. Th e upper limits for normal RI are 9.3 % for children 
younger than 1 year of age and 6.5 % for older children, assuming that, after 1 year of age, 
the physiologic incidence of GER in children is comparable with that in adults (5).
During both the MCTT and the pH evaluation, patients were fed normally (no supple-
mental tube feeding),executing normal activities, in their typical feeding position. CAPD 
112
C
ha
pt
er
 5
patients received their typical dialysis prescription, while the abdomen of NIPD patients 
was ﬁ lled with 40 mL/kg dialysate during the evaluation.
Results
Th e MCTT was normal in 6 of 8 patients (Figure 1); in 2 children, the hydrogen peak 
occurred early (after 30 and 40 minutes respectively).
Table 1 shows the results of the 24-hour pH monitoring. One of 8 patients (Patient 8) 
showed a mild pathological GER.
Discussion
A relatively small number of studies have been published on gastrointestinal function in 
children with chronic renal failure. Gastric dysrythmias, delayed gastric emptying and 
gastroesophageal reﬂ ux have been reported to play an important role in feeding distur-
bances (5-9).
In our study the MCTT was not prolonged. Th e early increase in breath hydrogen in 2 
patients may indicate bacterial overgrowth, but there were no clinical symptoms (such 
as diarrhoea) of bacterial overgrowth. In this study population, the presence of dialysis 
ﬂ uid in the abdomen did not seem to lead to inhibition of intestinal passage, as has been 
reported in adult patients (10).
Th e results of the 24-hour pH monitoring demonstrate that there was no pathological GER 
in any but 1 patient. Th e slightly increased RI in this patient was associated with a period 
of emotional distress during which the esophageal pH fell below 4. Th ese results are in 
strong contrast with the results of other studies , which report the presence of pathologi-
cal GER in a large percentage of children with chronic renal failure but not in children 
who were not treated with dialysis (5,6). Th e results of the present study may suggest that 
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Figure 1 Mouth to caecum transit time in 8 children treated with CAPD. Normal ranges 
are indicated by the shaded area.
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peritoneal dialysis does have a beneﬁ cial eﬀ ect on gastrointestinal motility. 
In conclusion, the feeding disturbances in our patients are not caused by a pathological 
GER or delayed intestinal passage. Th e presence of dialysis ﬂ uid in the children’s abdomen 
did not inﬂ uence the results.
Patient Sex Age (years) CAPD/NIPD Reﬂ ux index (%)
1 M 7.0 CAPD 6.0
2 M 2.0 NIPD 6.2
3 F 0.8 NIPD 4.8
4 M 4.8 CAPD 3.0
5 M 9.1 NIPD 0.8
6 F 1.5 NIPD 2.6
7 F 14.7 CAPD 1.2
8 F 4.6 NIPD 7.3
Table 1. Results of 24 hour pH recordings.
CAPD = continuous ambulatory peritoneal dialyis; 
NIPD = nightly intermittent peritneal dialysis
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Abstract
Objective: Obstruction of the peritoneal dialysis (PD) catheter is a well-known clinical 
problem. During stable PD, hypoﬁ brinolysis occurs resulting in ﬁ brin deposits, which may 
lead to subsequent obstruction of the catheter. Local ﬁ brinolytic therapy with a plasminogen 
activator, such as urokinase which activates the conversion of inactive plasminogen to active 
plasmin, enhances the degradation of ﬁ brin and may lead to dissolution of the ﬁ brin clot.
Th e aim of the study was to retrospectively evaluate the eﬀ ect of local ﬁ brinolytic therapy 
with urokinase on PD catheter obstruction.
Subjects: Th e study group consisted of 17 children on PD (8 boys, 9 girls) with a mean age 
of 7.0 years (range 0.2 – 16.0). One child presented twice with an obstructed catheter.
Methods: After catheter obstruction (inﬂ ow, outﬂ ow, or both) 15,000 IU Urokinase was 
injected into the catheter which was subsequently clamped for 1 hour. PD was restarted 
immediately.
Results: A positive eﬀ ect of urokinase therapy was seen in 9 out of 18 obstructions 
(50%). Catheter obstruction associated with peritonitis was observed in 5 children. 
All of them were successfully treated with urokinase (100%).    
Obstructions occured either early (within two weeks after catheter implementation), 
or late (> two weeks after catheter implementation).    
Two out of eight early obstructions (25%) were successfully unblocked with urokinase. 
Of the 10 late obstructions 7 (70%) showed a positive result to urokinase.   
Evaluation of the unsuccessful treatment with urokinase therapy showed mechanical ob-
structions in all of the patients (omentum wrapping in 8 and catheter malpositioning in 
1 patient). No systemic side eﬀ ects of urokinase were seen during treatment.
Conclusion: We conclude that local ﬁ brinolytic therapy with urokinase is a safe procedure 
and an eﬀ ective treatment for all obstructed PD catheters, except for catheters obstructed 
by mechanical causes. Mechanical obstructions tend to occur early (< 2 weeks after imple-
mentation). Obstructions associated with peritonitis occur relatively late (> 2 weeks after 
implementation).
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Introduction
Catheter obstruction is a serious complication of peritoneal dialysis (PD) in dialysis-de-
pendent patients. Eight to ﬁ fteen percent of both adults and children on PD present with 
a malfunctioning catheter sometime during dialysis [1-3]. Th is problem can be due to 
either mechanical obstruction, such as catheter malposition or omentum wrapping, or to 
obstruction of the catheter lumen, caused by ﬁ brin deposits.
As previous studies reported, intraperitoneal hypercoagulation and a relative hypoﬁ brinoly-
sis have been observed during stable PD, resulting in an accelerated ﬁ brin turnover [4].
During peritonitis, the imbalance of the ﬁ brinolytic system appears even more marked 
[5]. Fibrin deposits may subsequently obstruct the PD catheter. Local ﬁ brinolytic therapy 
with a plasminogen activator, such as urokinase which activates the conversion of inactive 
plasminogen to active plasmin, enhances the degradation of ﬁ brin and may dissolve the 
obstructing ﬁ brin clot.
In this study, we retrospectively (September 1987 to May 2001, a period of 14 years) 
evaluated the eﬀ ect of ﬁ brinolytic therapy with urokinase in children with PD catheter 
obstruction. 
Patients and Methods
Th e study population comprised 17 children (8 boys, 9 girls) receiving PD for end-stage 
renal failure (ESRF). Th e median age was 7.0 years (range 0.2 to 16.0 years). Mean duration 
of PD was 7.7 months (range 0 to 69 months). All children presented with an obstructed 
catheter. One child experienced two episodes of catheter obstruction. Causes of ESRF and 
clinical data of the children are summarised in Table 1. 
In 5 children, peritonitis occurred within 1 month prior to PD catheter obstruction. 
Peritonitis was deﬁ ned as cloudy peritoneal eﬄ  uent associated with an increased number 
of white blood cells (>100/mm3) and/or micro-organisms in the dialysate eﬄ  uent, dem-
onstrated by culture [6]. 
Catheter obstructions (inﬂ ow, outﬂ ow, or complete obstruction) ocurred either early (≤ 14 
days after catheter implementation) or late (> 14 days after catheter implementation).
Unblocking the catheter with urokinase was attempted following a published protocol [7]. 
First, the occluded catheter was manually ﬂ ushed with 10 ml NaCl 0.9% using a sterile 10 
ml syringe. Th en 15.000 IU urokinase, dissolved in 5 ml NaCl 0.9% was injected into the 
catheter, which was subsequently clamped for 1 hour. Afterwards the catheter was ﬂ ushed 
with 2 x 10 ml NaCl 0.9%. Peritoneal dialysis was restarted immediately. Urokinase therapy 
was considered eﬀ ective if the catheter was unblocked and restored to function.
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Results
A positive eﬀ ect of urokinase therapy was seen in 9 of 18 (50%) obstructions. All ﬁ ve PD 
catheter obstructions associated with peritonitis were successfully treated with urokinase. 
In contrast, only 4 of 13 (31%) children without peritonitis responded well to therapy.
Two of eight (25%) early obstructions and seven of ten (70%) late obstructions showed 
positive results with urokinase. Most (80%) obstructions associated with peritonitis oc-
curred late. Early (25%) obstructions were not associated with peritonitis, except for one 
occluded catheter, and responded poorly to urokinase treatment. 
N Sex Age 
in 
years
Cause of ESRF Dura-
tion  PD 
(months)
P < 1 
month
Obstruction Weeks 
since 
Catheter 
Insertion
Eﬀ ect 
Uroki-
nase
 1  M 2.1 TIN 8.1 – Outﬂ ow 32.6 Yes
 2  M 0.3 PBS 1.2 + Outﬂ ow 5.4 Yes
 3  M 6.1 PUV 7.7 + Outﬂ ow 0.7 Yes
 4  F 0.2 Hyperoxaluria 0.0 – ? 0.0 No
 5  F 0.2 Hypoplasia 2.1 + Complete 9.0 Yes
 6  F 12.6 HSN 0.3 – Complete 1.3 No
 7  F 5.7 Acro-osteolysis 5.9 – Complete 24.9 No
 8  F 10.2 Unknown 0.3 – Complete 1.3 No
 9  M 14.5 Hypoplasia 8.2 – Outﬂ ow 0.0 No
10a*  F 1.9 Dysplasia 2.5 – Outﬂ ow 11.0 No
10b*  F 2.2 Dysplasia 6.5 – Complete 17.3 Yes
11  M 14.4 FSGS 69 + ? 89.6 Yes
12  F 12.1 Cystinosis 0.3 – Outﬂ ow 1.6 No
13  M 0.2 Secundary to 
cardiac disease
0.1 – Complete 1.0 Yes
14  M 1.0 Dysplasia + TIN 0.1 − Outﬂ ow 4.0 Yes
15  F 14.9 Anti-GBM GN 0.5 – Outﬂ ow 2.0 No
16  M 11.7 Dysplasia 7.2 – Outﬂ ow 31.7 No
17  F 16.0 Unknown 11 + Inﬂ ow 47.7 Yes
* the same child
Table 1: Clinical data of the patients studied. (ESRF = end-stage renal failure; 
PD = peritoneal dialysis; PBS = prune belly syndrome; TIN = tubulointerstitial 
nephritis; PUV = posterior urethral valves; HSN = Henoch-Schönlein nephritis; 
FSGS = focal segmental glomerulosclerosis; anti-GBM = antiglomerular basement 
membrane; GN = glomerulonephritis)
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Successful ﬁ brinolysis was achieved in 5 of 9 outﬂ ow obstructions, 2 of 6 complete obstruc-
tions and in the only inﬂ ow obstruction observed. In two children, the kind of obstruction 
was not adequately documented; One showed a positive eﬀ ect to urokinase infusion.
Surgical evaluation of the unsuccessful treatments with urokinase therapy showed mechani-
cal obstructions in all of the children: direct omental adhesions to the catheter (wrap) in 8 
children and catheter blocking by the intestine in 1 child. Six of nine mechanical obstruc-
tions occurred early. No systemic side eﬀ ects of urokinase, such as a bleeding tendency, 
were observed during or after treatmant.
Discussion
Excessive ﬁ brin formation due to hypercoagulation and hypoﬁ brinolysis in PD patients 
contributes to ﬁ brin clots and subsequent obstruction of PD catheters [4]. During peri-
tonitis, intraperitoneal hypercoagulation increases even more [3,8]. Th is might explain 
the increased rate of catheter obstruction during peritonitis and the excellent results to 
urokinase therapy observed in children with peritonitis in the present study. 
Recent unavailability of urokinase on the market underscores the need for a substitute 
ﬁ brinolytic agent. Tissue plasminogen activator (tPA) probably is an acceptable alterna-
tive [9, 10]. 
In summary, we conclude that local ﬁ brinolytic therapy with urokinase is a safe and ef-
fective treatment for PD catheter obstruction. Urokinase should always be administered 
in obstructions following peritonitis or occurring more than two weeks after catheter 
implementation. In early obstructions and in children without peritonitis, obstructions 
are probably caused by anatomical structures, through mechanisms unlikely to respond to 
urokinase. However, before surgery for an occluded PD catheter is considered, an attempt 
with intraluminal urokinase should always be made. 
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Abstract
Background. Acute renal failure in infants and small children is generally treated with 
peritoneal dialysis. Immediately after catheter implantation dialysis has to be started. Early 
dialysate leakage can complicate the eﬀ ectiveness of dialysis. Fibrin glue applicated in the 
external part of the tunnel may stop dialysate leakage and prevent surgical intervention. 
Th e use of ﬁ brin glue in the treatment of peritoneal dialysis catheter leakage in children 
was studied .
Methods. Fibrin glue was used in eight children on peritoneal dialysis (age 4 - 57 months) 
in whom dialysate leakage was seen in the ﬁ rst 24 to 48 hours after catheter insertion. Th e 
dialysis volume initially administrated was 20ml/kg body weight. Th e ﬁ brin glue (1ml) 
was applied in the external part of the subcutaneous catheter tunnel through the exit site 
as closely to the cuﬀ  as possible. Th e occurrence of dialysate leakage and complications 
such as exit-site or tunnel infection and peritonitis were evaluated.
Results. Nine single cuﬀ  straight Tenckhoﬀ  catheters were implanted in eight children. In 
ﬁ ve cases no subcutaneous tunnel was created. One child had a catheter replacement due 
to obstruction of the catheter: on both occasions catheter leakage was seen and treated with 
ﬁ brin glue. In all eight patients no relapse of dialysate leakage was seen after application 
of the ﬁ brin glue. During the time of peritoneal dialysis neither exit-site infections nor 
tunnel infections or peritonitis occurred.
Conclusion, Fibrin glue is a successful, simple and safe substance for the treatment of 
peritoneal dialysate leakage in infants and small children with acute renal failure treated 
with peritoneal dialysis.
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Introduction 
Th e convenience, simplicity and relative safety have made peritoneal dialysis a frequently 
used dialytic modality in acute renal failure in pediatric patients (1-3). In the case of acute 
renal replacement therapy, immediate dialysis following catheter insertion is needed. In 
contrast to the guidelines on chronic peritoneal dialysis (4), it is not possible to leave 
the catheter for two weeks in order to allow initial healing. As a consequence peritoneal 
dialysis catheter leakage may occur, which can complicate the eﬀ ectiveness of dialysis and 
also bears the potential risk of infection at the catheter exit-site or tunnel and cuﬀ  (5), 
which may eventually result in catheter removal. Leakage also complicates the calcula-
tion of the ﬂ uid balance. In those cases where temporary interruption of dialysis and/or 
reduction of dialysate volumes do not solve the leakage, replacement of the peritoneal 
catheter is indicated. Fibrin glue applied in the external part of the catheter tunnel may 
stop dialysate leakage and prevent infections and surgical interventions (6). Fibrin glue is 
a two component system of solutions of ﬁ brinogen and thrombin. Th e mixture of these 
two solutions mimics the ﬁ nal stages of the coagulation cascade. In the presence of cal-
cium ions thrombin cleaves the ﬁ brinogen chains to form ﬁ brin monomers, which then 
polymerize to produce a physiologic ﬁ brin clot. Th e ﬁ brin clot degrades in time (10-14 
days) by natural ﬁ brinolysis (7).
Th e aim of this study was to examine the eﬀ ectiveness of ﬁ brin glue in the treatment of 
peritoneal dialyisis catheter leakage in infants and children suﬀ ering from acute renal failure 
who were treated with peritoneal dialysis.
Subjects and methods
Fibrin glue was applied in 8 infants and children in whom dialysate leakage was seen in the 
ﬁ rst 24 to 48 hours after catheter insertion. Patients varied in age from 4 months to 4.5 
years. Th ey all suﬀ ered from acute renal failure for which they were treated with peritoneal 
dialysis. Th e dialysis volume initially administered was 20 mL/ kg body weight. Dialysate 
leakage was conﬁ rmed by a positive glucose dipstick of the leaking ﬂ uid. One mL of ready-
to-use ﬁ brin glue (Tissucol® Duo 500, Baxter AG, Vienna, Austria) was applied in the 
external part of the catheter tunnel through the exit site, as close as possible to the cuﬀ . Th e 
ﬁ brin glue kit consists of two compartments. One compartment contains an aprotonine 
solution; aprotinine: 3000 KIG/mL, ﬁ brinogen: 70-110 mg/mL, ﬁ bronectin: 2-9 mg/mL, 
factor VIII: 10-50 U/mL. Th e other compartment contains a thrombin-CaCl2 solution; 
thrombin 500 U/mL and CaCl2 40 µmol/mL. Th e contents of the two compartments are 
mixed by means of a special mixing head and subsequently applied with a blunt needle. 
Desinfection with iodine or alcohol was avoided because of possible interference with the 
ﬁ brin glue, which will undo its action. 
Evaluation for dialysate leakage, exit site or tunnel infections and peritonitis episodes was 
performed daily after application of the ﬁ brin glue, with a maximum of 60 days.
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Results
In our study group of 8 patients in whom peritoneal dialysis catheter leakage occurred 
within 24 to 48 hours after catheter placement, ﬁ brin glue was applied for 9 times. In 
1 child ﬁ brin glue was applied twice, as a catheter replacement was performed due to 
subsequent obstruction of the catheter by omentum. In all 9 cases no relapse of dialysate 
leakage was seen after application of the ﬁ brin glue.
Th e catheters of the study group comprised 9 single cuﬀ , straight Tenckhoﬀ  catheters. In 
5 cases the catheter was placed straight into the abdominal wall, while in the other 4 cases 
a subcutaneous tunnel was created. Placement of the catheter occurred according to the 
preferred method of the surgeon concerned. Th e patients in the study group were dialysed 
for a median period of 7 days after treatment with ﬁ brin glue and 1 patient was transferred 
to chronic peritoneal dialysis. 
During the follow-up period after application of the ﬁ brin glue there were no exit site or 
tunnel infections observed nor were there any peritonitis episodes. Th ere were no other 
adverse events observed.
Discussion
Th e application of ﬁ brin glue in the external part of the catheter tunnel is an eﬀ ective 
treatment of periluminal catheter leakage in children on acute peritoneal dialysis.
Although continuous renal replacement therapies, such as continuous hemoﬁ ltration and 
continuous hemodiaﬁ ltration, are gaining popularity in the treatment of acute renal failure 
in children (8,9), peritoneal dialysis remains less technology- and labor-intensive and can 
be utilized in many clinical settings (1-3,10). Th e most important factors inﬂ uencing the 
choice of a dialysis-modality is the indication for dialysis and the overall clinical status of 
the patient (10). 
Th e use of peritoneal dialysis in acute renal failure generally implicates that the peritoneal 
dialysis catheter will be used immediately after placement. Th is increases the risk of perilu-
minal leakage of dialysis ﬂ uid, which can complicate the eﬀ ectiveness of dialysis and increase 
the risk of infections at the exit site, catheter tunnel and peritoneal membrane (5). 
Reports on leakage of peritoneal dialysis catheters vary from 2.6% to 22% in adults (11-
14). In peritoneal dialysis in children similar ﬁ gures are reported (15-17). Generally used 
treatments for dialysate leakage include lower dialysate volumes, temporary rest from 
peritoneal dialysis and surgical repair (18).  
Fibrin glue has been used in a wide variety of surgical procedures over the last 20 years 
(7,19,20). It is used for topical hemostasis and sealing. Experiences with the use of ﬁ brin 
glue in peritoneal dialysis catheter leakage is still limited. Joﬀ e was the ﬁ rst to describe 
his positive experiences using ﬁ brin glue in 6 adult patients on chronic peritoneal dialysis 
(6). Sojo et al. demonstrated some good results in preventing dialysate leakage in children 
by applying ﬁ brin glue at the time of catheter implantation (5). Our study is the ﬁ rst to 
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report results in a group of children suﬀ ering from acute renal failure for which they were 
treated with peritoneal dialysis. Our data conﬁ rm the previous results (5,6), suggesting 
that the application of ﬁ brin glue is a succesfull method of treating periluminal peritoneal 
dialysis catheter leakage which prevents the need of catheter replacement and occurrence 
of infections. 
It is concluded that ﬁ brin glue is a succesful, simple and safe substance for the treatment of 
peritoneal dialysis catheter leakage in infants and children with acute renal failure who are 
treated with peritoneal dialysis. Fibrin glue prevents the occurrence of infections and the 
need for surgical intervention. It deserves a major role in treatment of peritoneal dialysis 
catheter leakage in both adult and pediatric patients. 
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General discussion
Children with chronic renal failure who are treated with peritoneal dialysis, are largely 
dependent on the functionality of their peritoneum as a dialyzing membrane. Although 
most children will be transplanted, it has to be kept in mind that sooner or later resump-
tion of dialysis will be needed in case of graft failure. Th e use of glucose containing dialysis 
solutions and the occurrence of peritonitis episodes are responsible for progressive loss of 
the peritoneal permeability. Th e treatment itself is a burden both for the child and his or 
her parents, which is in part due to frequent subcutaneous drug application.
In the chapters of this thesis several clinical studies have been described that might give 
better understanding in therapies that will decrease the burden placed on these children, 
both physical and psychosocial.
Th e three general issues that are discussed include (1) peritoneal transport with the use 
of glucose polymer-based dialysis solutions, (2) intraperitoneal drug application and (3) 
complications of peritoneal dialysis. Possible future investigations will be indicated.
Peritoneal transport with the use of icodextrin
Th e peritoneal equilibration test (PET) is a well-known method used to assess the peritoneal 
transport abilities (1). In order to obtain more information on peritoneal ﬂ uid transport, 
the test has been adapted: dextran 70 was added to the test solution as a volume marker. 
Experiences with this modiﬁ ed and standardized PET, which is also called standard peri-
toneal permeability analysis, have been described both in pediatric and in adult patients 
(2‒4). When ﬂ uid kinetics are corrected for body surface area, this allows for comparison 
of results between patients. Comparison of peritoneal ﬂ uid kinetics between children and 
adults using standardized test methods show that there are no diﬀ erences between those 
two groups (2,3). Th is implies that the transport characteristics of the peritoneum of both 
adults and children are basically the same. Th is was conﬁ rmed in chapter 2: ﬂ uid kinetics 
and solute transport for a 3.86% glucose solution were found to be similar in children 
and adults. 
Icodextrin is a dialysis solution containing glucose polymers, which act as a colloid osmotic 
agent. Because glucose polymers are hardly absorbed, icodextrin is especially eﬀ ective dur-
ing long-term dwells. In adult patients extensive experiences using icodextrin have been 
described. In children however experience using this polymer-based dialysis solution was 
limited to one study describing sustained net ultraﬁ ltration during long term dwell and a 
metabolism similar to that found in adult patients (5). No studies were available concern-
ing the ﬂ uid kinetics of icodextrin. Th e most applied mathematical approach of peritoneal 
transport is the three-pore model as described by Rippe et al (6‒8). Based on this model, 
aquaporins play a minor role in transcapillary ultraﬁ ltration (TCUF) using icodextrin. 
Analysis of sodium sieving during the ﬁ rst hour of a dwell showed an absence of a drop 
in the D/P ratio of sodium using icodextrin. A decrease of the D/P ratio was seen using 
3.86% glucose. In the presence of an aquaporin mediated water ﬂ ow the amount of water 
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transported will exceed the amount of solutes transported. Th is will cause a dilution of 
the dialysate. Our results conﬁ rm the value of the three-pore model as a model of perito-
neal transport. Fluid kinetics of icodextrin were compared with results previously found 
in adult patients (chapter 1; 9). In spite of the use of standardized test methods, TCUF 
and marker clearance (MC) were found to be signiﬁ cantly lower in children compared 
to adults. Net ultraﬁ ltration (NUF) was similar in both groups. As ﬂ uid transport while 
using icodextrin seems to be mainly a result of water transport through the small pores 
our results suggest that the pediatric study group must have lower small pore area available 
for transport. We did not ﬁ nd any other indications that support this idea. Th e results of 
our study also suggest that the group of children studied had a 3 times higher amount of 
functional aquaporins. Lai et al. demonstrated an upregulation of aquaporin-1 in cultured 
human peritoneal mesothelial cells upon exposure to glucose, which is both time- and 
dose-dependent (10,11). It was not clear how long the eﬀ ect of glucose lasted. Th ey also 
speculated that long-term PD might lead to decreased expression of aquaporin-1 caused 
by denudation of mesothelial cells. An in vivo study in rat peritoneal tissue conﬁ rmed that 
expression of aquaporin-1 is upregulated upon exposure to glucose and hyperosmolality 
(12). In cultured rat mesothelial cells upregulation of aquaporin-1 was attended with an 
increase in osmotic induced water permeability (12). A recent study showed that aquapo-
rins can be inactivated while they remain on the cell surface, but it is not yet clear which 
mechanism is responsible for the inhibition (13). Immunohistochemical analysis of human 
peritoneum showed that expression of aquaporin-1 is correlated with the amount of water 
transported through the aquaporins after 1 hour after equilibration with 3.86% glucose 
(14). Th e diﬀ erences found in ﬂ uid kinetics of icodextrin between the two study groups 
suggest that the peritoneum of children has another distribution of the three types of func-
tional pores as compared to the peritoneum of adults. Th is is in strong contrast with the 
belief that peritoneal transport, and subsequently the distribution of the pores, is the same 
in children and adults. Nevertheless our study also showed that the clinical eﬃ  cacy of the 
aquaporins is similar in children and adults. It could be hypothesized that the diﬀ erences 
found in ﬂ uid kinetics using icodextrin between the pediatric and the adult study group 
are a consequence of diﬀ erences in exposition to diﬀ erent glucose concentrations and/or 
diﬀ erences in duration of PD rather than diﬀ erences in peritoneal composition. Further 
studies are needed to elucidate the cause of the diﬀ erences in ﬂ uid kinetics of icodextrin 
between pediatric and adult patients. Recently Smit et al have published a method which 
enables direct quantiﬁ cation of free water transport, calculated from a single PET. Th is 
method will oﬀ er a quick possibility to evaluate aquaporin mediated water transport in 
children and adults (15). Additionally immunohistochemical analysis of the peritoneum 
of both pediatric and adult patients is indicated, in order to compare distribution and 
activity of aquaporins.
Adequate peritoneal transport characteristics and ﬂ uid kinetics are of major importance for 
establishing the optimal treatment modality (16,17). Th e most widely used technique is the 
peritoneal equilibration test, which utilizes the dialysate over plasma (D/P) concentration 
for urea, creatinine and the D/D0 ratio for glucose. Johnsson et al (18) argued that the 
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unrestricted pore area (A0/∆x) is a better indicator to estimate the capacities of a peritoneal 
membrane of individual patients as compared to the information provided by the PET. Th is 
unrestricted pore area is the product of the number of perfused capillaries in contact with 
the dialysate, the number of pores per capillary, the area of each of these pores (A0) and 
the average diﬀ usion distance between blood and dialysate (∆x). It was suggested that the 
use of the PET should be replaced by the use of the personal dialysis capacity test (PDC), 
since PET data fail to provide clear information of changes in underlying mechanisms 
in the peritoneal membrane, like the relative pore distribution and pore size, while PDC 
data allow for determination of the transport characteristics of the peritoneal membrane 
in individual patients. Fischbach et al (19) subsequently were able to demonstrate that the 
unrestricted pore area can also be estimated adequately from PET data, which proves its 
value as a tool to obtain data on peritoneal transport characteristics, based on our current 
knowledge of capillary physiology. Th erefore it does not seem to be of additional value to 
change our 6 month routine of performing a PET into performance of a PDC. Further 
studies are indicated to investigate the usefulness of PDC in a way to minimize the need 
of nursing time and decrease the burden placed on the children and parents. 
One of the parameters that aﬀ ects the individual area available for transport of solutes and 
ﬂ uid is the ﬁ ll volume used (20). Fill volume is also one of the determinants of the intra-
peritoneal pressure (IPP). We demonstrated an inﬂ uence of diﬀ erent osmotic agents on 
IPP, which is dependent on the diﬀ erences in ﬂ uid kinetics: an increase in intraperitoneal 
volume causes an increase in intraperitoneal pressure (chapter 2). In our strive of creating 
optimally individualized dialysis prescriptions it seems to be of additional value to measure 
IPP in combination with the personal peritoneal exchange capacity. Although PET is used 
in many pediatric centers, measurement of IPP in children is still not widely applied. A 
recent publication might be helpful to increase the application of IPP measurement, since 
it oﬀ ers a useful description of how the measurement should be performed and how the 
values should be interpretated (21). Another major reason for not measuring IPP was a 
lack of reference values in children, since data available were obtained in only small study 
groups. Th erefore we measured IPP in a larger group of children, under standardized cir-
cumstances. We used an intraperitoneal volume of 1200 ml/m2, which is an appropriate 
ﬁ ll volume in terms of tolerance and eﬀ ectiveness. Application of ﬁ ll volumes higher than 
1200 ml/m2 will not contribute to a gain in dialysis eﬃ  ciency, since the unrestricted pore 
area will not increase any further and higher intraperitoneal volumes will cause an increase 
in IPP, which will not be accepted by the child (22). Recently it was shown that Physi-
oneal, a new dialysis ﬂ uid with a more neutral pH and containing lower concentrations 
of glucose degradation products as compared to the conventional lactate-buﬀ ered dialysis 
ﬂ uids, induces a lower IPP, implying an enhanced ﬁ ll volume tolerance (23). Randomized 
studies on peritoneal dialysis outcome parameters will be needed to elucidate the added 
value of IPP measurements to optimize individual dialysis prescriptions. 
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Intraperitoneal drug administration 
Th e presence of a permanent catheter into the peritoneal cavity allows for the intraperito-
neal administration of drugs. Antibiotics are generally administered intraperitoneally, in 
case of peritoneal dialysis-associated peritonitis. Th e most recent guidelines for the initial 
treatment of peritonitis in adult patients propose the use of a ﬁ rst- and a third-genera-
tion cephalosporin (24). We were able to demonstrate that the use of such a combination 
(cefazolin / ceftazidime) also leads to good results in the treatment of peritonitis in pedi-
atric patients (chapter 4). Th is combination of cephalosporins avoids the routine use of 
aminoglycosides, and thus the risk of nephrotoxicity and ototoxicity. In spite of the results 
we presented in a group of unselected patients, the ﬁ rst edition of treatment guidelines 
for pediatric patients recommends the use of this combination only in a small selected 
group of patients with very low risks (25). Although a ﬁ rst-generation cephalosporin will 
not be eﬃ  cient against methicillin-resistant organisms, its use is preferred in the light of 
the emergence of glycopeptide-resistant organisms and the toxic eﬀ ects of glycopeptides. 
Our results support the value of the use of a ﬁ rst- and a third-generation cephalosporin 
as empiric initial therapy. Once culture results and bacterial susceptibilities are known, a 
glycopeptide can be introduced if necessary. Besides the advantages of cefazolin, which are 
mentionned previously, this antibiotic also seems to be suitable for intermittent dosing. 
As most children receive a nocturnal intermittent PD regimen, they need to switch to a 
CAPD regimen in case of continuous dosing of antibiotics. Intermittent intraperitoneal 
antibiotic administration will avoid the need to switch to another dialysis regimen. Schae-
fer et al. are the ﬁ rst to describe good results with intermittent intraperitoneal treatment 
of peritonitis in children, using a combination of a glycopeptide and ceftazidime (26). 
Good results have also been reported with the intermittent intraperitoneal administration 
of cefazolin in adults (27). Th is suggests that treatment of peritoneal dialysis-associated 
peritonitis with intermittent intraperitoneal cefazolin and ceftazidime might be an inter-
esting alternative for the continuous administration of this combination in children who 
receive an intermittent dialysis regimen. Currently our group is investigating the use of 
an intermittent dosing regimen.
Subcutaneous administration of drugs is painful and psychologically distressing. As a result 
noncompliance with erythropoietin has been reported for a majority of adult patients, and 
this also will be the case in pediatric patients. During the last years positive results have 
been reported with the intraperitoneal administration of erythropoietin in children. It was 
shown that, when administered in a small amount of dialysis ﬂ uid, erythropoietin was very 
well absorbed (28) and maintenance dosages were similar to those required during subcu-
taneous therapy (29). We were able to conﬁ rm these results for a larger patient group and a 
longer treatment period (chapter 3). Th e development of novel erythropoietin stimulating 
protein (NESP), or darbepoietin alfa, might be of help to increase the compliance. NESP 
is a hyperglycosylated erythropoietin analogue, containing two extra carbohydrate chains. 
NESP has a three-fold longer half-life than erythropoietin and therefore is able to maintain 
hemoglobin levels as eﬀ ectively and safely as erythropoietin but requires less frequent dosing 
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(30,31). Since the introduction of NESP to the market it already has gained an important 
place in the treatment of renal anemia in patients suﬀ ering from chronic renal failure (32). 
Because there are no data available with respect to the intraperitoneal administration of 
NESP, a randomized comparative study of intraperitoneal administration of NESP and 
erythropoietin is needed. If once a week administration of NESP will be suﬃ  cient, intra-
peritoneal administration of this drug will be applicable in almost all PD patients, as it 
will hardly interfere with the acquaintance of good dialysis adequacy. 
Another drug that is traditionally administered subcutaneously, and which is used by many 
pediatric patients with chronic renal failure is recombinant human growth hormone. Treat-
ment of the growth hormone resistance results in improved growth. To achieve this, daily 
injections are needed. Changing this mode of administration to intraperitoneal would be 
of help in decreasing the burden placed on the child and his or her caregivers. Positive 
results have been reported concerning the absorption of intraperitoneal growth hormone 
(33, 34). Also intraperitoneal administration of growth hormone in prepubertal peritoneal 
dialysis patients has proven to be eﬀ ective and well tolerated (34). Th is suggests that the 
intraperitoneal route of administration can be preferred in the treatment of short stature 
among children on peritoneal dialysis. Dialysis adequacy is a major factor of concern 
with daily intraperitoneal administration of growth hormone. As most children are able 
to achieve an acceptable dialysis dose with a nightly intermittent dialysis regimen, daily 
intraperitoneal administration of growth hormone during the daytime will not interfere with 
dialysis adequacy. However in those patients in need of a daytime dwell for suﬃ  cient dialysis 
adequacy, intraperitoneal administration of growth hormone will be out of reach. 
Complications of peritoneal dialysis
Children with chronic renal failure often suﬀ er from anorexia and sometimes vomiting. 
Although little research has been performed on the gastroenterological aspects of chronic 
renal failure in children, impaired gastric emptying appears to play a role in the patho-
genesis of these gastrointestinal symptoms. Gastric emptying in children is diﬃ  cult to 
evaluate properly. Th e main reason is the lack of safe and non-invasive methods to measure 
gastric emptying in children: intubation studies are invasive and time consuming, radios-
cintigraphic methods cause a radiation burden and ultrasonographic evaluation is largely 
dependent on the experience of the investigator. Th e 13C octanoic acid breath test, a new 
non-invasive breath test, oﬀ ers a reliable alternative with a non-radioactive character. Th e 
test has been adapted for infants and children (35,36) and has an excellent reproducibility 
(37). In chapter 5 we evaluated the intestinal passage in pediatric patients treated with 
peritoneal dialysis by a lactulose hydrogen breath test and did not ﬁ nd any indications for 
delayed gastric emptying or pathological gastroesophageal reﬂ ux. Th e development of the 
13C octanoic acid breath test might be very useful to enlarge our limited understanding of 
the cause of these gastrointestinal symptoms in children with end stage renal disease. 
In chapter 6 positive results are presented using urokinase as ﬁ brinolytic agent in the case 
of ﬁ brin obstruction of a peritoneal dialysis catheter in pediatric patients. As a conse-
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quence of intraperitoneal hypercoagulation and relative hypoﬁ brinolysis during PD, ﬁ brin 
obstruction is one of the major causes of catheter malfunctioning in pediatric PD (38). 
Especially in catheter obstructions occurring more than 14 days after catheter implanta-
tion and in obstructions following peritonitis urokinase should always be administered. 
In early obstructions and in children without peritonitis, obstructions are mostly due to 
other causes, like catheter malpositioning and omentum wrapping which demand surgical 
intervention. Nevertheless an attempt with intraluminal ﬁ brinolytic therapy should always 
be made. Unfortunately the future availability of urokinase on the market is uncertain. 
Th is demands new experiences with an alternative ﬁ brinolytic agent. Tissue plasminogen 
activator (tPA) has a mechanism of action similar to that of urokinase and is a useful 
alternative for local ﬁ brinolytic therapy in pediatric PD. Some good results with the use 
of tPA in adult patients have been presented (39, 40) and future studies will establish the 
eﬀ ect of tPA also in children.
Another complication related to the peritoneal dialysis catheter is periluminal leakage of 
dialysis ﬂ uid. Leakage of dialysis ﬂ uids can complicate the eﬀ ectiveness of dialysis and 
increases the risk of infections at the exit site, catheter tunnel and peritoneal membrane. 
Treatments for catheter leakage generally include decreasing of dialyate volumes, temporary 
rest from dialysis and surgical repair. Especially in acute peritoneal dialyis these treatment 
options cause an unacceptable delay in dialysis. Th e application of ﬁ brin glue in the external 
part of the catheter tunnel has proven to be an eﬀ ective treatment of periluminal catheter 
leakage, preventing the need of catheter replacement or other time-consuming treatments 
(chapter 7). Recently this has been conﬁ rmed by another group (41). Besides its use in 
acute peritoneal dialysis, the use of ﬁ brin glue also deserves a major role in treatment of 
peritoneal dialysis catheter leakage in chronic peritoneal dialysis.
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Summary
Peritoneal dialysis is the preferred modality for renal replacement therapy in children with 
chronic renal insuﬃ  ciency. In the present thesis several clinical studies performed in chil-
dren treated with peritoneal dialysis have been described. Transperitoneal transport was a 
major issue. Little has been published concerning the use of 7.5% icodextrin in children. 
Fluid kinetics with this glucose polymer based dialysis ﬂ uid were studied and compared 
with results in adult patients. Th e eﬀ ect of two diﬀ erent dialysis ﬂ uids on intraperitoneal 
pressure was determined. Th e transport of drugs from the peritoneal cavity to the blood 
was the starting-point for assessment of the eﬀ ectiveness of intraperitoneal administra-
tion of erythropoietin and antibiotics. An attempt was made to get more insight into 
gastroenterological complications of peritoneal dialysis and experiences are described with 
the use of urokinase in dialysis catheter obstruction and the use of ﬁ brin glue in dialysis 
catheter leakage
An overview of our current knowledge on peritoneal dialysis in children has been pre-
sented in the General Introduction. A review is given of the peritoneal anatomy and its 
characterization with respect to transperitoneal transport. Peritoneal transport of ﬂ uid and 
solutes is discussed and a mathematical model for transperitoneal transport is introduced. 
Methods to evaluate peritoneal transport characteristics were introduced and discussed 
with respect to their application in patient care. Factors inﬂ uencing peritoneal permeability 
were explained and several mediators involved in changes in peritoneal permeability were 
discussed. Developments in peritoneal dialysis solutions were discussed and special attention 
was paid to experiences with a glucose polymer based dialysis solution. Th e rationale for 
intraperitoneal administration of drugs was explained and experiences with intraperitoneal 
administration of erythropoietin and antibiotics were discussed
In Chapter 1 the peritoneal equilibration test (PET) was applied to study the peritoneal 
transport characteristics using 7.5% icodextrin and 3.86% glucose. Additionally a com-
parison was made with peritoneal transport characteristics in adults. Solute transport and 
ﬂ uid kinetics in children were similar for 7.5% icodextrin and 3.86% glucose, except 
for transcapillary ultraﬁ ltration (TCUF). Th is was explained by the slow ultraﬁ ltration 
rate of 7.5% icodextrin. Peritoneal transport characteristics for the glucose solution were 
similar for children and adults, but for 7.5% icodextrin diﬀ erences were found in TCUF 
and marker clearance, which equals the disappearance of ﬂ uid from the peritoneal cav-
ity. Comparison of transport parameters and peritoneal characteristics reveals that there 
seem to be diﬀ erences between the peritoneal transport pathways in children and adults. 
Th e absolute water ﬂ ow through the aquaporins is similar in children and adults, which 
implies that the clinical eﬃ  cacy of these water channels is similar. However further studies 
are needed to explore the diﬀ erences in the amount and the functionality of the diﬀ erent 
peritoneal transport pathways and the consequences of these diﬀ erences for the use of 
diﬀ erent osmotic agents. 
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In Chapter 2 normal values for intraperitoneal pressure (IPP) in children were established 
and the eﬀ ect of 3.86% glucose and 7.5% icodextrin on IPP during a 4-hour dwell were 
studied. IPP values were in the same range as those previously obtained in smaller pa-
tient groups. During a 4-hour dwell with 3.86% glucose a signiﬁ cant relation was found 
between IPP and TCUF. Th is result was likely mediated by an important increase of the 
intraperitoneal volume (IPV). During a dwell with 7.5% icodextrin no such relation was 
seen, which was explained by the small increase in IPV. Smaller children (children with a 
small BSA) have a more pronounced rise in IPP due to an increase of the IPV as compared 
to children with a larger BSA. It was concluded that the diﬀ erent eﬀ ect of a colloid and a 
crystalloid osmotic agent on the change in IPP is due to the diﬀ erences in ﬂ uid kinetics 
of these osmotic agents.
In Chapter 3 the intraperitoneal administration of recombinant human erythropoietin has 
been addressed. Erythropoietin was injected in small bags, containing 50 mL NaCl 0.9% 
solution. Th e solution was instilled after complete drainage of the abdomen for a 10- to 
12-hour dwell during the day. It was demonstrated that intraperitoneal administration of 
erythropoietin leads to an eﬀ ective treatment of renal anemia. Maintenance dosages needed 
were similar to those when using the subcutaneous administration route. Our ﬁ ndings 
suggest that intraperitoneal erythropoietin should replace the subcutaneous administration, 
especially when adequate dialysis dose is obtained with a nightly dialysis regimen.
In Chapter 4 the eﬀ ectiveness of the combination of cefazolin and ceftazidime in the 
initial treatment of peritoneal dialysis-associated peritonitis episodes was evaluated. When 
peritonitis was diagnosed continuous antibiotic therapy was started, and depending on 
the causative microorganism therapy was adjusted. In 1 out of 50 episodes cefazolin and 
ceftazidime had to be replaced by another antibiotic medication. In all cases cloudiness of 
peritoneal ﬂ uid and clinical symptoms improved within 3 days after initiation of antibi-
otic therapy. In 90% of the peritonitis episodes no relapse occurred after ending therapy. 
Th erefore this combination of a ﬁ rst- and a third-generation cephalosporin is eﬀ ective in 
the treatment of peritoneal dialysis-associated peritonitis. Nephrotoxic and ototoxic side 
eﬀ ects of aminoglycosides are avoided using this combination.
In Chapter 5 the mechanisms underlying feeding disturbances in children treated with 
peritoneal dialysis were studied. Th e possible existence of a pathological reﬂ ux was exam-
ined and the intestinal passage was quantiﬁ ed by measuring the mouth-to-caecum transit 
time. Gastrointestinal motor function was not disturbed, which was in contrast with re-
sults obtained in studies performed by others. Th e presence of dialysis ﬂ uid did not have 
a negative eﬀ ect on gastrointestinal motor function. Th erefore we were not able to show a 
causative relation between gastrointestinal function and feeding disturbances.
In Chapter 6 the eﬀ ectiveness of ﬁ brinolytic treatment with urokinase in children with 
peritoneal dialysis catheter obstruction was evaluated. Urokinase enhances degradation of 
ﬁ brin which may dissolve an obstructing ﬁ brin clot. In case of catheter obstruction 15000 
IU of urokinase was injected into the catheter. An excellent eﬀ ect of urokinase therapy 
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was seen in obstructions associated with peritonitis and in those obstructions occurring 
more than 14 days after catheter implantation. In obstructions occurring within 14 days 
after catheter implantation and in children without peritonitis, obstructions were more 
often caused by mechanisms unlikely to respond to urokinase. Because of the noninvasive 
character of intraluminal urokinase therapy, an attempt with urokinase should always be 
made, before surgery is considered.
Another peritoneal dialysis catheter related complication is periluminal leakage of dialysis 
ﬂ uid. In Chapter 7 a noninvasive therapy for catheter leakage was evaluated in children 
with acute peritoneal dialysis. Fibrin glue, a mixture of solubilized ﬁ brinogen and thrombin, 
was applied in the external part of the catheter tunnel in children presenting with catheter 
leakage within the ﬁ rst 24 to 48 hours after catheter insertion. No relapse of dialysate 
leakage was seen after application of ﬁ brin glue, and no infections occurred. Fibrin glue 
is a successful, simple and safe substance for the treatment of periluminal dialysis leakage 
in acute peritoneal dialysis, and surgical intervention is avoided. Th erefore, it deserves a 
major role in the treatment of peritoneal dialysis catheter leakage in peritoneal dialysis 
patients of all ages. 
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Samenvatting
Peritoneaal dialyse is de meest aangewezen methode voor nierfunctie vervangende therapie 
voor kinderen met een chronische nierinsuﬃ  ciëntie. In dit proefschrift worden klinische 
studies beschreven, die uitgevoerd werden bij kinderen die behandeld worden met peri-
toneaal dialyse. Transperitoneaal transport was daarbij een belangrijk onderwerp. Tot nu 
toe is er weinig gepubliceerd over het gebruik van icodextrine op de kinderleeftijd. De 
vloeistofkinetiek van deze dialysevloeistof -die gebaseerd is op glucosepolymeren- werd 
bestudeerd en vergeleken met resultaten die eerder waren verkregen bij volwassenen. Tevens 
werd het eﬀ ect van twee verschillende dialysevloeistoﬀ en op de intraperitoneale druk werd 
bekeken. Het transport van medicijnen van de peritoneaal holte naar het bloed vormde 
het uitgangspunt voor studies naar de eﬀ ectiviteit van de intraperitoneale toediening van 
antibiotica en erythropoiëtine. Een poging werd gedaan om meer inzicht te krijgen in de 
gastroenterologische complicaties die gepaard gaan met peritoneaal dialyse. Voorts werd 
een beschrijving gegeven van de ervaringen die werden opgedaan met het gebruik van 
urokinase in het geval van obstructie van peritoneaal dialysecatheters, en het gebruik van 
weefsellijm in het geval van lekkage langs peritoneaal dialysecatheters.
In de Algemene Inleiding wordt een overzicht gegeven van de huidige kennis op het gebied 
van peritoneaal dialyse op de kinderleeftijd. De hoofdlijnen van de peritoneale anatomie 
worden beschreven en de karakterisering van de peritoneaal membraan met betrekking 
tot het transperitoneale transport. Het peritoneale transport van vloeistof en vaste deeltjes 
wordt besproken en het meest gebruikte wiskundige model voor transperitoneaal transport 
wordt uitgelegd. Verschillende methodes voor het evalueren van peritoneale transportka-
rakteristieken worden uitgelegd en bekeken in relatie tot de zorg voor de patiënt. Factoren 
die van invloed zijn op de permeabiliteit van de peritoneaal membraan worden uitgelegd 
en verscheidene mediatoren die betrokken zijn bij veranderingen in de permeabiliteit van 
de peritoneaal membraan worden besproken. 
Ontwikkelingen in peritoneaal dialysevloeistoﬀ en worden besproken en extra aandacht 
wordt besteed aan de ervaringen die zijn opgedaan met het gebruik van dialysevloeistof ge-
baseerd op glucosepolymeren. De basis voor de intraperitoneale toediening van medicijnen 
wordt uitgelegd en eerder gepubliceerde ervaringen met het intraperitoneale toediening 
van erythropoiëtine worden weergegeven.
In Hoofdstuk 1 wordt de peritoneaal equilibratie test (PET) toegepast voor de bestudering 
van peritoneale transportkarakteristieken tijdens het gebruik van icodextrine en 3,86% 
glucose. Aansluitend wordt er een vergelijking gemaakt met peritoneale transportkarakteris-
tieken bij volwassenen. Het transport van vaste deeltjes en de vloeistofkinetiek bij kinderen 
waren vergelijkbaar voor icodextrine en 3,86% glucose, behalve voor de transcapillaire 
ultraﬁ ltratie (TCUF). Dit laatste wordt verklaard door de langzame, gestage ultraﬁ ltratie die 
icodextrine te weeg brengt. De peritoneale transportkarakteristieken voor de glucosevloeistof 
waren vergelijkbaar voor kinderen en volwassenen, maar voor de icodextrinevloeistof wer-
den er verschillen gevonden in de TCUF en de klaring van de marker, die gebruikt wordt 
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als maat voor verdwijning van vloeistof uit de peritoneaal holte. Berekeningen lieten zien 
dat de hoeveelheid en de eﬀ ectiviteit van de aquaporines bij de volwassenen lager lag dan 
bij de kinderen. De veronderstelling is dat dit verschil verklaard wordt door een verschil 
in blootstelling aan glucose en/of een verschil in behandelingsduur. Er is daarom reden 
om aan te nemen dat icodextrine goed toepasbaar is op de kinderleeftijd, maar verdere 
studies zullen nodig zijn om de onderliggende oorzaak voor het verschil in vloeistofkine-
tiek te doorgronden.
In Hoofdstuk 2 worden normaalwaarden vastgesteld voor de intraperitoneale druk op de 
kinderleeftijd, en het eﬀ ect van 3,86% glucose en icodextrine op de intraperitoneale druk 
wordt bestudeerd. De waardes die gevonden werden voor de intraperitoneale druk bevon-
den zich in dezelfde range als de gepubliceerde waardes, die verkregen waren in kleinere 
studie groepen. Gedurende een verblijfsperiode van 4 uur met 3,86% glucose veranderde 
de intraperitoneale druk signiﬁ cant in relatie tot de TCUF. Dit was waarschijnlijk een 
gevolg van de toename in het intraperitoneale volume. Gedurende een zelfde verblijfspe-
riode met icodextrine werd een dergelijke relatie niet gevonden. Dit kan worden verklaard 
door de geringe toename van het intraperitoneale volume. Bij kleinere kinderen is er een 
meer uitgesproken stijging van de intraperitoneale druk ten gevolge van een stijging van 
het intraperitoneale volume, dan het geval is bij kinderen met een groter lichaamsopper-
vlakte. Dit eﬀ ect werd alleen waargenomen tijdens de verblijfsperiode met 3,86% glucose. 
Daarom is het waarschijnlijk, dat de verschillen die gezien worden tijdens verblijfsperiodes 
met verschillende dialysevloeistoﬀ en, een gevolg zijn van de verschillen in vloeistofkinetiek 
van de betreﬀ ende dialysevloeistoﬀ en.
In Hoofdstuk 3 wordt de intraperitoneale toediening van recombinant humaan erythro-
poiëtine beschreven. Erythropoiëtine werd geïnjecteerd in kleine zakjes met daarin 50 
ml NaCl 0,9%-oplossing. Na een complete drainage van de buik, liet men de oplossing 
inlopen, waarna deze overdag gedurende 10 tot 12 uur achterbleef in de peritoneaal holte. 
Er werd aangetoond dat intraperitoneale toediening van erythropoiëtine leidt tot een ef-
fectieve behandeling van renale anemie. De benodigde onderhoudsdoseringen waren gelijk 
aan de onderhoudsdoseringen die nodig zijn bij gebruik van de subcutane toedieningsweg. 
Onze bevindingen suggereren dat de subcutane toediening van erythropoiëtine dient te 
worden vervangen door intraperitoneale toediening, met name als er met nachtelijke 
intermitterende dialyse een adequate dialysedosis wordt verkregen.
In Hoofdstuk 4 wordt de eﬀ ectiviteit van de combinatie cefazoline en ceftazidim voor de 
initiële behandeling van peritoneaal dialyse-geassocieerde peritonitis geëvalueerd. Zodra 
peritonitis was gediagnostiseerd werd gestart met continue behandeling met antibiotica. 
Afhankelijk van de sensitiviteit van het micro-organisme werd de behandeling vervolgens 
aangepast. In één van de 50 peritonitis episodes was het nodig om cefazoline en ceftazidim 
te vervangen door een ander antibioticum. In alle gevallen verbeterden de troebelheid van 
het dialysaat en de klinische symptomen binnen drie dagen na het starten van de antibiotica. 
In 90% van de gevallen trad er geen recidief op na het beëindigen van de behandeling. Er 
is daarom reden om aan te nemen dat deze combinatie van een eerste- en een derde-gene-
157Summary
ratie cephalosporine eﬀ ectief is voor de behandeling van peritoneaal dialyse-geassocieerde 
peritonitis. De nefrotoxische en ototoxische bijwerkingen van aminoglycosides, die vaak in 
andere schema’s worden gebruikt, worden vermeden bij het gebruik van deze combinatie 
van antibiotica.
In Hoofdstuk 5 worden de mechanismen bestudeerd die ten grondslag liggen aan de voe-
dingsstoornissen, die gezien worden bij kinderen die behandeld worden met peritoneaal 
dialyse. Het mogelijke bestaan van een pathologische reﬂ ux werd onderzocht en de snelheid 
van de maag-darmpassage werd gekwantiﬁ ceerd door meting van de doorgangstijd van 
mond tot coecum. De motorische functie van het maagdarmkanaal bleek niet gestoord te 
zijn, dit in contrast tot de resultaten die verkregen zijn met eerder gepubliceerde studies. 
Daarnaast had de aanwezigheid van dialysaat in de peritoneaal holte geen negatieve invloed 
op de motorische functie van het maagdarmkanaal. Daarom was het niet mogelijk om een 
oorzakelijk verband tussen de functie van het maagdarmkanaal en de voedingsstoornissen 
aan te tonen.
In Hoofdstuk 6 werd de behandeling van obstructie van de peritoneaal dialysecatheter 
met intraluminaal toegediend urokinase geëvalueerd. Urokinase versnelt de degradatie 
van ﬁ brine, hetgeen mogelijk kan leiden tot het oplossen van een obstruerende ﬁ brine 
prop. In het geval van obstructie van een catheter werd 15000 IE urokinase in de cathe-
ter geïnjecteerd. Er werd een uitstekend resultaat waargenomen van de behandeling met 
urokinase in die gevallen van obstructie die gerelateerd waren aan een peritonitis episode, 
en bij obstructies die meer dan 2 weken na plaatsing van de catheter optraden. Bij de 
obstructies die binnen 14 dagen na het plaatsen van de catheter optraden en bij kinderen 
die geen peritonitis hadden, werden de obstructies grotendeels veroorzaakt door mechanis-
men die niet reageerden op behandeling met urokinase, zoals verstopping met omentum. 
Vanwege het niet-invasieve karakter van de intraluminale behandeling met urokinase, 
lijkt het daarom geïndiceerd om altijd hiermee een poging te wagen, voordat chirurgisch 
ingrijpen wordt overwogen.
Een andere belangrijke complicatie van peritoneaal dialyse is de lekkage van dialysevloeistof 
uit de cathetertunnel. In Hoofdstuk 7 wordt een evaluatie gegeven van de niet-invasieve 
behandeling van catheterlekkage bij kinderen die behandeld worden met acute peritone-
aal dialyse. Weefsellijm -een mengsel van ﬁ brinogeen- en thrombine-oplossingen- werd 
toegediend in het externe gedeelte van de cathetertunnel bij kinderen die zich gedurende 
de eerste 24 tot 48 uur na plaatsing van de catheter presenteerden met lekkage. In geen 
van de gevallen zagen we een recidief van de lekkage en/of het optreden van infecties. 
Weefsellijm lijkt een succesvolle, eenvoudige en veilige substantie voor de behandeling van 
lekkage van dialysevloeistof bij peritoneaal dialyse. Hierdoor is chirurgische interventie 
overbodig. Daarom wordt geconcludeerd dat weefsellijm een belangrijke plaats verdient 
bij de behandeling van lekkage van de peritoneaal dialysecatheter bij patiënten van alle 
leeftijden. 
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Als er sprake is van een verminderde nierfunctie, dan is het lichaam niet voldoende in 
staat om afvalstoﬀ en en overtollig water uit te scheiden. Het hebben van een slechte nier-
functie op de kinderleeftijd heeft ernstige gevolgen, zoals het optreden van botontkalking, 
groeistoornissen, aderverkalking en beschadiging van de hersenen. Uiteindelijk kunnen 
kinderen ook overlijden aan de gevolgen van hun slechte nierfunctie. Om deze ernstige 
gevolgen te voorkomen bestaan er mogelijkheden om de nierfunctie te vervangen. De 
meest ideale manier om de nierfunctie te vervangen is de uitvoering van een niertransplan-
tatie, waarbij de patiënt een nier krijgt van een familielid of van een overledene. Door het 
beperkte aantal donornieren dat beschikbaar is, zijn de wachtlijsten hiervoor echter lang. 
Naast de niertransplantatie zijn er ook andere technieken beschikbaar om de nierfunctie 
te vervangen: bloedspoeling en buikspoeling. 
Bij bloedspoeling, of hemodialyse, vindt de zuivering van het bloed direct plaats via de 
bloedbaan. Bij buikspoeling, ook wel peritoneaal dialyse genoemd, worden de afvalstof-
fen in het bloed en het overtollige water via het buikvlies aan het lichaam onttrokken. 
Hiertoe wordt er een dialysevloeistof via een verblijfscatheter (een catheter die permanent 
door de buikwand heen gaat) in de buikholte gebracht. De dialyse vloeistof heeft bepaalde 
eigenschappen waardoor de afvalstoﬀ en en het overtollige water via de bloedvaatjes in het 
buikvlies naar de dialyse vloeistof diﬀ underen (het natuurkundige proces waarbij ongelijke 
vloeistoﬀ en vermengen). Door na een bepaalde tijd de dialyse vloeistof weer uit de buik 
te laten lopen en er vervolgens weer nieuwe dialyse vloeistof in te laten lopen, wordt het 
bloed gezuiverd en het overtollige water afgevoerd en zo vervang je dus de functie van de 
nieren. Naast de dialyse is het belangrijk dat kinderen zich aan een dieet houden en dat 
ze een beperkte hoeveelheid vocht innemen. 
Peritoneaal dialyse is de meest gebruikte behandeling voor het vervangen van de nierfunctie 
op de kinderleeftijd. In het merendeel van de gevallen worden de kinderen ’s nachts, tijdens 
hun slaap, gedialyseerd. Een machine zorgt er voor dat de dialyse vloeistof in de buik loopt 
en er later weer uitloopt. Dit heeft een aantal voordelen ten opzichte van hemodialyse. Zo 
kan peritoneaal dialyse thuis worden gedaan, zodat kinderen gewoon overdag naar school 
kunnen, terwijl kinderen voor hemodialyse vaak 3 keer per week naar het ziekenhuis moeten 
komen. Door de aanwezigheid van de verblijfscatheter in de buikwand hoeven de kinderen 
niet elke keer geprikt te worden. En verder hebben kinderen die behandeld worden met 
peritoneaal dialyse vaak meer vrijheid in hun dieet en hun vochtinname dan kinderen die 
behandeld worden met hemaodialyse. Ondanks de voordelen blijft het echter een feit dat 
peritoneaal dialyse een zware belasting vormt voor zowel de ouders als het kind. 
In dit proefschrift worden een aantal studies beschreven, die uitgevoerd zijn bij kinderen 
die behandeld worden met peritoneaal dialyse. Een belangrijk uitgangspunt voor het 
merendeel van die studies was het transport van deeltjes en vloeistof over het buikvlies. 
Er wordt aangenomen dat er een drietal verschillende soorten (hele kleine) gaatjes in het 
buikvlies zitten, die bepalend zijn voor de mate waarin deeltjes over het buikvlies kun-
160
P
ar
t V
I
nen diﬀ underen. Door de grootste gaatjes kunnen macromoleculen zoals eiwitten, door 
de kleine gaatjes kunnen kleine deeltjes zoals ureum en glucose, en door de ultra kleine 
gaatjes kan alleen water diﬀ underen. Door die gaatjes vindt dus transport plaats van het 
bloed naar de buikholte, maar tevens vindt er transport plaats van vloeistof en deeltjes van 
de buikholte naar het bloed.
In het eerste deel van dit proefschrift worden de eﬀ ecten bestudeerd van icodextrine. Ico-
dextrine is een dialysevloeistof die zich onderscheidt van andere dialyse vloeistoﬀ en omdat 
er geen glucose in zit. Hoewel glucose heel goed in staat is om afvalstoﬀ en en overtollig 
vocht aan de bloedbaan te onttrekken, zorgt het tegelijk voor een beschadiging van het 
buikvlies. Met behulp van een gestandaardiseerde test (de peritoneaal equilibratie test, 
kortweg PET) is er gekeken naar de eﬀ ecten van icodextrine op het transport van deeltjes 
en vloeistof over het buikvlies. Tevens is er gekeken of het gebruik van icodextrine eﬀ ect 
had op de druk die ontstaat in de buikholte (IPP). We zagen dat de eﬀ ecten van icodextrine 
op het transport over het buikvlies vergelijkbaar zijn met de eﬀ ecten die beschreven zijn 
bij volwassen patiënten. Onze resultaten duiden er op, dat het transport over het buikvlies 
niet exact hetzelfde lijkt te verlopen bij kinderen en volwassenen. Toch is het uiteindelijke 
eﬀ ect van icodextrine wel hetzelfde. Verdere studies zullen nodig zijn om de verschillen in 
transport beter te bestuderen, om ze goed te kunnen verklaren. De druk in de buikholte 
liep niet zo snel op tijdens het gebruik van icodextrine, als tijdens het gebruik van een 
glucose houdende vloeistof. Dit konden we verklaren door het feit dat er relatief weinig 
water aan de bloedbaan werd onttrokken tijdens het gebruik van icodextrine, waardoor 
het volume in de buikholte ook minder toenam.
In het tweede deel van dit proefschrift worden ervaringen besproken, die opgedaan zijn 
met de toediening van medicijnen via de verblijfscatheter. We hebben gekeken naar de ef-
fectiviteit van een combinatie van antibiotica voor de behandeling van buikvliesontsteking. 
Buikvliesontsteking is een vervelende complicatie van peritoneaal dialyse. De gebruikte 
combinatie van antibiotica heeft als voordeel dat ernstige bijwerkingen, zoals doofheid of 
een verdere achteruitgang van de nierfunctie niet optreden. Uit onze resultaten blijkt dat de 
combinatie van antibiotica goed geschikt is voor de behandeling van buikvliesontsteking. 
Voor de toediening van een aantal medicijnen is het nodig om meerdere keren per week 
een prik te geven. Dit vormt vaak een zware belasting voor zowel het kind als de ouders. We 
hebben onderzocht of het mogelijk is om bloedarmoede goed te behandelen door erythro-
poiëtine via de verblijfscatheter in de buikholte te spuiten in plaats van toediening via de 
gebruikelijke prikjes onder de huid. We zagen dat de behandeling van de bloedarmoede 
net zo goed verliep en dat er ook niet meer van het medicijn nodig was dan voorheen.
In het derde deel worden studies besproken die betrekking hebben op enkele veel voorko-
mende complicaties van peritoneaal dialyse. Zo hebben veel kinderen die behandeld 
worden met peritoneaal dialyse last van misselijkheid en een gebrek aan eetlust. We hebben 
gekeken of er afwijkingen zijn in de functie van de maag en de darmen, die de oorzaak 
kunnen zijn voor deze voedingsproblemen, maar we hebben geen aanwijzingen gevonden 
dat dat ook zo is.
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Een andere complicatie van peritoneaal dialyse is het verstopt zitten van de verblijfscatheter. 
Dit heeft als gevolg dat er niet gedialyseerd kan worden. We zagen dat in veel gevallen 
voorkomen kan worden dat er geopereerd moet worden om een nieuwe catheter te plaatsen, 
door de verstopping in de catheter te behandelen met urokinase. Verder bleek, dat lekkage 
van een verblijfscatheter behandeld kan worden met het aanbrengen van weefsellijm op de 
plaats van de lekkage. Ook deze relatief eenvoudige en niet-belastende behandeling kan 
voorkomen dat het nodig is om een chirurg te vragen om een catheter te verwisselen. 
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Tijdens een promotieplechtigheid wordt doorgaans 1 persoon in de schijnwerper gezet. 
Het feit dat ik vandaag ook in die schijnwerper mag gaan staan is te danken aan heel veel 
mensen, die allemaal een eigen steentje hebben bijgedragen aan de totstandkoming van 
dit proefschrift. Ik ben al die mensen daar heel erg dankbaar voor. Een aantal van hen wil 
ik hier graag in het bijzonder noemen.
Mijn eerste woord van dank gaat uit naar alle kinderen en hun ouders, die het mogelijk 
hebben gemaakt om de studies uit te voeren die hier beschreven worden. Met name de 
dagen waarop de PETs uitgevoerd werden waren soms erg lang en (ondanks de videoban-
den) ook erg saai. Zonder jullie inzet waren we nergens geweest!
Prof. dr. C.H. Schröder, beste Cock, dank voor de intensieve begeleiding gedurende de 
afgelopen jaren. Door je enorme enthousiasme voor de peritoneaal dialyse, de laagdrem-
peligheid waarmee je beschikbaar was voor het beantwoorden van allerlei vragen, en de 
hoge snelheid van corrigeren van de manuscripten was het een genoegen om aan dit 
proefschrift te werken. Ook ben ik je erg dankbaar voor de mogelijkheden die je bood, 
om ervaring op te doen met de (internationale) presentatie van ons werk. Je steun in min-
dere tijden zal ik nooit vergeten!        
Prof. dr. L.A.H. Monnens, beste Leo, het meedenken bij de uitvoering van de studies en het 
kritische doorlezen van de manuscripten waardeer ik zeer. De relativerende opmerkingen 
(‘geloof je dat echt?’) zullen ook in de toekomst hun waarde behouden.  
Prof. dr. J.L. Willems, beste Hans, ik wil je graag bedanken voor je verhelderende inbreng 
tijdens de vele PD-besprekingen. Als chemicus keek je soms heel anders tegen de dingen 
aan, hetgeen voor mij erg waardevol was bij het verruimen van mijn blikveld. Verder heb 
ik veel plezier beleefd aan de manier waarop jij er voor kon zorgen dat het onderwerp van 
onze discussies weer werd teruggebracht naar het onderzoek.   
Dr. N.C.A.J. van de Kar, beste Nicole, je bent een grote steun voor me geweest bij de 
praktische uitvoering van de studies. Het was ﬁ jn om samen te werken.
De leden van de promotiecommissie professor Smits, professor Krediet en doctor van 
Hamersvelt dank ik voor het kritisch lezen van het manuscript.
Eén van de grootste nadelen van het doen van onderzoek, is dat het af en toe erg eenzaam 
werken is. Gelukkig had ik collega’s die me door die stille momenten heen trokken.  
Desiree Creemers, met jou deelde ik lange tijd een kamer en daarmee ook een hele hoop 
lief en leed. Ik bewonder je tomeloze hoeveelheid energie en de manier waarop jij je inzet 
voor je patiënten. Het is jammer dat ik maar twee paranymfen mag hebben ... 
Marja Koppejan-Stapel, dank voor je belangstelling en betrokkenheid. Marc Lilien, je 
bent me toch nog te snel af geweest…. Naast een cursus ‘jazz luisteren door de muur’ heb 
ik ook veel geleerd van jouw kritische houding in de wetenschap. Ik denk met heel veel 
plezier terug aan alle ‘nefrologische werkbesprekingen’ tijdens de lunch. 
Alle ‘Hommels’: Adriënne, Aline, Audrey, Berry, Bregje, Carry, Ida, Joke, Lex, Machteld, 
Marijke, Marja, Mirjam, Safta en Wilma wil ik graag bedanken voor hun betrokkenheid. 
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Madelon Kleingeld, dank voor je mentale steun en vriendschap! Ook de verpleegkundigen 
van de kinderdialyse-afdeling in Nijmegen, dank voor jullie gastvrijheid als ik weer een 
dagje gegevens zat te verzamelen. In het bijzonder wil ik de verpleegkundigen bedanken die 
alle PETs hebben uitgevoerd. Lida, het was een groot plezier om met je samen te mogen 
werken. Ik ken weinig mensen die zo precies én creatief zijn als jij. De constructie die jij 
bedacht om de intraperitoneale druk betrouwbaarder te meten is een ultieme uiting daarvan! 
Do, dank voor alle moeite die je hebt gestoken in de uitvoering van de PETs.
Loes …. Dank je wel voor alle logistieke hulp bij de verzending van alle proefschriften.
Marike Stadermann, ik vind het een grote eer dat jou stuk (hoofdstuk 6) een onderdeel 
vormt van mijn proefschrift. Maartje van der Vlugt wil ik bedanken voor haar inzet tijdens 
haar wetenschappelijke stage, die een belangrijke basis heeft gevormd voor hoofdstuk 2. 
Renske Raaijmakers heel veel succes met het voortzetten van deze onderzoekslijn. 
Mijn paranymfen, lieve Gerreke en Berber, ik waardeer het zeer dat jullie hier vandaag samen 
met mij willen staan. Onze mail wisselingen hielpen mij door de zwaarste momenten aan 
het begin van dit onderzoek heen en brachten tegelijk een hoop vrolijkheid.  
Berber Oldenbeuving, prachtig mens, ik bewonder de manier waarop jij geheel je eigen 
koers hebt leren varen. Jij liet me zien dat je gelukkiger kunt zijn nadat je een Grote Droom 
aan de kant hebt gezet. Ik ben trots op onze vriendschap.    
Gerreke Regelink, dierbare vriendin, de geograﬁ sche afstand tussen ons lijkt af en toe in 
de weg te staan, maar de basis van onze vriendschap is goud waard!
Vooral de afgelopen twee jaar heb ik ondervonden dat de steun van het ‘thuisfront’ on-
ontbeerlijk is.          
Mijn schoonouders, lieve Frits en Karin, dank jullie wel voor de steun en het klankbord 
dat jullie me hebben gegeven. Zullen de tropenjaren nu op zijn?   
Mijn ouders, lieve papa en mama, ik ben enorm trots om jullie dochter te zijn. Jullie 
laten me altijd weer zien waar het eigenlijk om hoort te draaien in deze wereld. Ik ken 
geen andere mensen die zoveel van zichzelf kunnen geven, zonder daar iets voor terug te 
willen hebben.         
Tijmen en Merle, jullie maken de kleuren in mijn wereld oneindig veel mooier en intensie-
ver! Hopelijk blijft er nu meer tijd over voor het allerleukste: samen spelen.  
Lieve, lieve Sander, jij bent mijn basis, de bodem van mijn bestaan. Jou eindeloze optimisme 
en je stuwende kracht hebben mij er doorheen gehaald. Zonder jou was dit proefschrift er 
simpelweg niet geweest. Op naar het volgende avontuur ……!?
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